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ABSTRACT
YI QIAO
DISSERTATION ADVISOR: GABOR T. MARTH
Unlike normal tissue cells, which contain identical copies of the same genome, tumors
are composed of genetically divergent cell subpopulations, or subclones. The abilities
to identify the number of subclones, their frequencies within the tumor mass, and the
evolutionary relationships among them are crucial in understanding the basis of tu-
morigenesis, drug response, relapse, and metastasis. It is also essential information
for informed, personalized therapeutic decisions. Studies have attempted to recon-
struct subclone structure by identifying distinct allele frequency distribution modes at a
handful of somatic single nucleotide variant loci, but this question was not adequately
addressed with computational means at the start of this dissertation work, and recent
efforts either enforce certain assumptions or resort to statistical procedure which cannot
guarantee the complete landscape of solution space.
This dissertation present a computational framework that examines somatic varia-
tion events, such as copy number changes, loss of heterozygosity, or point mutations,
in order to identify the underlying subclone structure. Chapter 2 discuss the presence
of intra-tumoral heterogeneity, and for historical interest, a method to reconstruct the
parsimonious solution based on simplifying assumptions in tumor micro-evolution pro-
cess. Analysis results on clinical datasets concerning Ovarian Serious Carcinoma and
Intracranal Germ Cell Tumor based on this method, which confirmed the genomic com-
plexity, are also presented.
Due to the reason that the linkage information i.e. whether two mutations are co-
localizing in the same cancer cell is lost during tissue homogenization and DNA frag-
mentation, common sample preparation steps used in whole genome profiling tech-
niques, often there are more than one subclone model capable of explaining the obser-
vation. Chapter 3 describes an extended method that is able to search for all models
consistent with the observation. Consequently, the solution to a specific input dataset
is then a set of possible subclone structures. The method then trim this solution space
in the case that more than one sample from the same patient are available, such as
the primary and relapse tumor pairs. Furthermore, a statistical framework is devel-
oped that, when further trimming is not possible, predicts whether two mutations are
co-localizing in the same subclone. The formal definition on the problem of subclone
structure reconstruction, as well as techniques to pre-process various types of genomic
variation data are given given here as well. Results on the analysis of published and
novel datasets, ranging from cancer types including Acute Myeloid Leukemia, Sinonasal
Undifferenciated Carcinoma and Ovarian Serious Carcinoma, and data types including
whole genome sequencing, copy number array, single nucleotide polymorphism array
and single nucleotide variant calls with deep sequencing are also included. They show
that the method is applicable to these wide range of cancer and data types, able to in-
dependently replicate the published conclusion based on manual reasoning, and gain
novel insights into the pattern of tumor recurrence and chemoresistance. It also shows
that the method can be valuable in prioritizing variants for function study.
Chapter 4 summarizes the entire work, and provide future prospects in subclonality
research.
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Introduction
T
O OUR BEST KNOWLEDGE, cancer arises due to the accumulation of somatic
mutations that one acquires throughout his or her life span. It is the
outcome of a Darwinian evolution process among cell populations in the
micro-environment provided by different tissues of an organ [1] that some cells ac-
quire alleles in “cancer-causing genes” [2, 3]. In the past thirty years, cancer-causing
genes have been categorized into two main types: oncogenes, which are inactivated in
normal cells and has the potential to cause cancer [4], and tumor suppressor genes,
which are normally activated and protect the cell from progressing towards cancer [5].
Mutation occurs for many different reasons, including exposure to mutagenic chemi-
1
cals, intrinsic error of the DNA repair mechanism, inherited mutation from fertilized
egg (“germline”) that confers to genome instability (“susceptibility”), exogenous DNA
materials from bacterial or viral infections, epigenetic changes and so on. Mutation
also comes in many different forms, which were defined, based on the scope of the
effect, as Single Nucleotide Variation (SNV), Insertion or Deletion (INDEL), chromoso-
mal rearrangements and Copy Number Variation (CNV) [1, 6]. Disruption of the normal
function of oncogenes and tumor suppressors leads to cellular phenotype such as self
sufficiency in growth signals, insensitivity to anti-growth signals, evasion of apoptosis,
limitless replicative potential, sustained angiogenesis1, and metastasis [7].
In this chapter, I will give a brief introduction to our current knowledge regarding
the complexity of cancer genome, the methods to study genomic variations, and latest
studies which revealed intra-tumoral heterogeneity.
1.1 COMPLEXITY OF CANCER GENOME
With the understanding of human genome, and the waves of technologies that have
come into exist especially the Next Generation Sequencing (NGS), the genome of can-
cer has been systematically studied through many efforts. Following the launching of
the Human Genome Project (HGP) in 1990, which could be considered as the first
step to unravel the puzzle of cancer genome, three major organizations, the Wellcome
Trust Sanger Institute, the National Cancer Institute (NCI), and the International Can-
cer Genome Consortium (ICGC) have been leading the efforts to generate high-quality
-omic data on more than 25,000 tumors for up to 50 types of cancers [8]. NGS not
only increased the resolution of genotype profiling, but also enabled the discovery of
novel mutations in new cancer-causing genes. Original assumption of a single uniform
background mutation rate (~1/Mb) turned out to be overly simplified. A recent study
initiated by the Broad Institute (BI) revealed that the mutation frequencies varied across
1The development of new blood vessels
2
cancer types and across patients within a cancer type through the analysis of 27 cancer
types [9]. The same study also showed that the heterogeneity in the mutational spec-
trum of tumors. For example, a cluster consisting of samples dominated by C>G or C>T
mutation in the context of TpC contains mostly cervical, bladder, breast and some head
and neck cancer patients. Consistent with this result, Nik-Zainal et al. [10] reported
that a cluster substitutions like C>T, C>A or C>G in TpCpX trinucleotides was found to
be associated with ER-positive2 breast tumors. In addition, two new types of mutations
were reported recently, chromothripsis3 [11, 12] and kataegis4 [10, 13, 14]. Chro-
mothripsis, which refers to a catastrophic phenomenon that the chromosomes appear
to be shattered and then stitched back together, was identified by the use of paired-
end NGS across multiple cancer samples [12, 15]. This process occurs in 2%− 3% of
human cancer [16, 17]. The mechanism was proposed as that erroneous chromosome
escapes from pulverization of chromosomal segments and undergoes aberrant reassem-
bly through non-homologous end-joining [12, 18]. Kataegis operates locally, generating
a hypermutation region characterized by multiple base substitutions. Though the mech-
anism remains unclear, the activation-induced deaminase (AID) and apolipoprotein B
mRNA-editing enzyme catalytic polypeptide-like (APOBEC) protein families are likely
to be involved [10, 19].
There have been several very detailed review articles summarizing the studies of
global cancer genome features [19–21]. Here we focus more on new studies (mainly in
late 2013 to 2014) that are not covered by these articles, summarizing the landscape
of somatic mutations in different types of cancer.
2Endocrine receptor (estrogen or progesterone receptor) positive
3a catastrophic phenomenon that the chromosomes appear to be shattered and then stitched back
together
4a hypermutation region characterized by multiple base substitutions
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1.1.1 COLORECTAL AND GASTRIC CANCER
Genetic aberration were detected in colorectal carcinoma (CRC) by the The Cancer
Genome Atlas (TCGA) through the analysis of whole exome sequencing, copy num-
ber, promoter methylation, and mRNA & microRNA expressions in 276 samples as well
as low coverage whole genome sequencing data in 97 samples [22, 23]. Hypermu-
tated tumors (defined as > 12 mutations per mega-base) were observed in 16% of the
CRC samples, three quarters of which had high levels of micro-satellite instability fre-
quently caused by the silencing of DNA mismatch-repair pathway gene MLH1 due to
the hypermethylation on its promoter region. 24 genes that were found significantly
mutated involved in several pathways such as the WNT signaling (APC, CTNNB1, SOX9,
TP53, FAM123B), PI3K pathway (IGF2, IRS2, PTEN, PIK3CA), the transforming growth
factor-β (SMAD2 and SMAD4), the RTK-RTS signaling pathway (KRAS, BRAF and ERBB
family), and chromatin remodeling (ARID1A).
Wang et al. [24, 25] carried out two studies to characterize genetic features of gas-
tric cancer. The earlier study performed exome sequencing on a small cohort in 2011
and discovered frequent ARID1A mutation in the MSI and Epsterin-Bar virus (EBV) sub-
groups. The recent one, based on whole genome sequencing of 100 paired tumor and
normal samples, identified new driver mutations (MUC6, CTNNA2, GLI3, RNF43, ZIC4
and others), in addition to previously known TP53, ARID1A, and CDH1 [25]. Specifi-
cally, authors found 6 RHOA mutations with the whole genome sequencing data, and
another 7 in a cohort of 67 diffuse-type tumors, which were recurrent hot spot muta-
tions and caused defective RHOA signaling.
1.1.2 LUNG CANCER
There are two histological subtypes of lung cancer: small-cell lung cancer (SCLC) and
non-small-cell lung cancer (NSCLC). NSCLC if further classified into squamous cell car-
cinoma (SCC), adenocarcinoma and large-cell carcinoma subtypes, with adenocarci-
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noma being the most common subtype of NSCLC. Exome and genome sequencing of
183 tumor/normal pairs revealed high somatic mutation rate as 12 mutations per mega-
base [26]. Mutations including recurrent somatic mutations in the splicing factor gene
U2AF1, RBM10, and ARID1A, as well as exonic alteration within EGFR and SIK2 kinases
were identified, and may be therapeutically targeted [26]. Another independent study
carried out in Korea consisted of RNA sequencing of 200 lung adenocarcinoma and iden-
tified novel driver mutations such as LMTK2, ARID1A, NOTCH2, and SMARCA4 [27]. A
comprehensive genetic profile was also generated from 178 lung SCC samples. A study
by the Broad Institute found 260 exonic mutations, 165 genomic rearrangements, and
323 segments of copy number alteration per tumor [28]. Further more, Vignot et al.
[29] carried out targeted NGS assay on primary and matched metastatic tumor pairs
NSCLC samples from 15 patients (8 with adenocarcinoma, 2 with large-cell carcinoma,
2 with basaloid and 3 with SCC), in which 63 known recurrent and 248 novel (likely
passenger) mutations were discovered.
SCLC is an aggressive lung tumor subtype with frequent metastasis and early death.
Rudin et al. [30] and Peifer et al. [31] independently reported exome, whole genome,
transcriptome and copy number alteration data from a total of more than 100 primary
SCLC tumors. Both studies found frequent inactivation of TP53 and RB1 [32]. Rudin
et al. identified 22 significantly mutated genes including genes encoding kinases (i.e.
STK38, LRRK2, PRKD3, and CDK14), Ras family regulators (i.e. RAB37, RASGRF1, and
RASGRF2) and chromatin-modifying proteins or transcriptional regulators (i.e. EP300,
DMBX1, MLL2, MED12L, TRRAP, and RUNX1T1). Peifer et al. [31] found recurrent mu-
tations in the PTEN, SLIT2, EPHA7, CREBBP, EP300, and MLL genes as well as FGFR1
amplifications.
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1.1.3 ADRENOCORTICAL CARCINOMAS
Adrenocortical carcinomass (ACCs) are rare and progressive cancers originating in the
cortex of adrenal gland. Assié et al. [33] reported alterations in known driver genes
(CTNNB1, TP53, CDKN2A, RB1, and MEN1) [34, 35] as well as new ones (ZNRF3, DAXX,
TERT, and MED12) by exome sequencing and Single Nucleotide Polymorphism (SNP)
array analysis of 45 ACCs samples. Specifically, a cell surface E3 ubiquitin ligase gene,
ZNRF3, was frequently mutated and is a potentially new tumor suppressor gene in-
volved in β-catenin pathway.
1.1.4 ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Esophageal squamous cell carcinoma (ESCC) is a subtype of esophageal cancer and
particularly common in China. Lin et al. [36] identified several new mutated genes
such as FAT1, FAT2, ZNF750, and KMT2D in addition to those already known such as
TP53, PIK3CA, and NOTCH1 by whole exome or targeted deep sequencing of 139 paired
ESCC along with CNVs of over 180 ESCC samples.
1.1.5 UROTHELIAL BLADDER CARCINOMA
Urothelial bladder carcinoma is the most common type of bladder cancer and so far
no molecularly targeted agents have been approved for the treatment of this disease.
As part of TCGA project, a very recent study (March 2014, [37]) analyzed 131 high-
grade muscle-invasive urothelial carcinomas to characterize genetic alterations with
data including DNA copy number, somatic mutations, mRNA and microRNA expres-
sion, protein and phosphorylated protein expression, DNA methylation, transcript splice
variation, gene fusion, viral infection, pathway perturbation, clinical correlates and
histopathology. 32 recurrent mutated genes were identified, which involve in cell-cycle
regulation (e.g. CDKN1A), epigenetic regulation (e.g. MLL2, ARID1A, KDM6A, and
EP300), and kinase signaling pathways (e.g. PIK3CA). Out of these 32 genes, 9 of them
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with> 5% frequency have not been reported as significantly mutated in any other TCGA
cancer types, which are CDKN1A, ERCC2, RXRA, ELF3, KLF5, FOXQ1, RHOB, PAIP1, and
BTG2.
1.1.6 UTERINE LEIOMYOMAS
Uterine leiomyomas is a benign smooth muscle neoplasm but affects the health of
women. Mehine et al. [38] performed whole genome sequencing and gene expression
profiling on 38 uterine leiomyomas from 30 women and investigated clonal origin of tu-
mors from different patients, driver events in Complex Chromosomal Rearrangements
(CCRs) and candidate targets of chromosome 7q deletion. Identical or shared variants
among separate tumor nodules suggested the same origin of those nodules and addi-
tional rearrangements could suggest the relation of clonal evolution among nodules.
Surprisingly, interconnected CCR resembling chromothripsis, which is often associated
with advanced stage of cancers and a poor prognosis in other studies [39], was ob-
served frequently among these benign nodules. Finally, authors proposed a potential
mechanism model for leiomyoma development including events such as MED12 muta-
tion, biallelic loss of FH, translocation of the HMGA2 and RAD51B loci and aberrations
at the COL4A5/COL4A6 locus.
1.1.7 MANTLE CELL LYMPHOMA
Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma5.
Whole transcriptome sequencing (RNAseq) of 18 primary tissue and 2 cell line, and
exome sequencing of 56 primary tissue samples respectively in two studies have found
novel recurrent mutations in NOTCH1, RB1, WHSC1, POT1, and SMARCA4 in addition
to ATM, CCND1, MLL2, and TP53 [38, 40]. Zhang et al. [38] further carried out chro-
matin structure and epigenetic profiling of normal B cells and MCLs and found that
5Any of a large group of cancers of lymphocytes (http://www.cancer.gov/cancertopics/
types/non-hodgkin)
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frequent somatic mutations were associated with open chromatin.
1.1.8 CHRONIC LYMPHOCYTIC LEUKEMIA
Chronic lymphocytic leukemia (CLL), like other types of leukemia, has heterogeneous
clinical and biological behavior. Previously three independent whole exome and whole
genome sequencing studies [41–43] identified several mutations including TP53, ATM,
NOTCH1, MYD88 and splicing factor SF3B1. A recent study showed transcriptional
profile by performing deep RNA sequencing in different subpopulations of normal B-
lymphocytes and CLL cells from a cohort of 98 patients [44]. Higher expression of genes
involved in metabolic pathways and lower expression of genes related to sliceosome,
proteasome and ribosome were observed in CLL samples. B-cell receptor (BCR), JAK-
STAT signaling and the cytosolic DNA-sensing pathways were shown to be particularly
enriched in CLL.
1.2 GENOMIC PROFILING METHODS
In the 1970s, banding patterns of a person’s chromosomes, or the karyotype, has been
the primary tool for the clinical assessment of patients with a variety of genomic ab-
normalities. Later, methods such as fluorescence in situ hybridization (FISH) and its
derivative methods, spectral karyotyping (SKY) or multiplex-FISH (M-FISH) [45, 46]
were used to map DNA sequences to specific regions of human genomes, which allowed
a higher resolution than the standard G-banding approaches. FISH can also be used to
identify gene copy number variations by more or fewer fluorescent dots in somatic cells.
Comparative Genomic Hybridization (CGH), a more advanced, FISH-based technique,
was developed to study the gain and loss of chromosomal regions. Briefly, genomic
DNA are isolated and fragmented from both control subject and experimental subject,
and labeled with green and red fluorescence respectively. Then, two DNA samples are
pooled and hybridized with normal chromosomes (known as probes). As a result, yel-
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low fluorescence represents no alteration in experimental subject, whereas red or green
represents copy number gain and loss. By using this method, Shayeteh et al. [47] dis-
covered the amplification of PIK3CA in ovarian cancer. Useful as they have proven to
be, these methods are not suitable for large-scale, high-resolution mapping of the entire
genome.
1.2.1 ARRAY COMPARATIVE GENOME HYBRIDIZATION
Array comparative genome hybridization (aCGH) is a method that combines the princi-
ples of CGH and microarray [48]. The probe chromosomes are immobilized on a glass
slide in an ordered fashion. The size of the probes can vary from tens to thousands of
base pairs based on the areas of interest. The DNA fragmentation from a test sample
and a reference sample are directly comparable to the standard CGH procedure. After
applying two genomic DNA to the microarray, digital imaging systems are used to cap-
ture and quantify the relative fluorescence intensities of the labeled DNA. Not only did
aCGH enable the discovery of more genetic alteration types, such as sub-telomeric rear-
rangements [49] and peri-centromeric rearrangements [50], but also made the analysis
of large number of samples (e.g. 8789 clinical cases [50]) possible.
1.2.2 SANGER SEQUENCING
Developed by Sanger et al. in 1977 [51, 52], the first chain-terminating, by-synthesis
sequencing method has been widely adopted, and put in heavy use, until only recently
with the rise of NGS. Sanger sequencing relies on the addition of dideoxynucleotides
(ddNTPs), along with normal deoxynucleotides (dNTPs), so that the DNA polymer-
ization process is halted randomly after incorporating a ddNTP which lacks the 3’-OH
group to form the phosphodiester bond with the next base. Traditionally, the sequenc-
ing process is divided into four separate experiments, with each experiment containing
all the dNTPs and one specific ddNTP. After the synthesize is complete, the product of
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the experiments are loaded into separate lanes for gel electrophoresis to sort the DNA
fragments by their length. Finally, the sequence is determined by reading the bands on
the electrophoresis from short to long, based on the lane they are in. For example, a
fragment of length 10bp in the lane that represents the experiment in which ddCTP is
added indicates that the nucleotide on the 10th bp in the original sequence is G.
Based on the same principle, automated procedures [53, 54] are developed that, by
using florescent labeled ddNTPs, the DNA synthesize is carried out in one experiment,
followed by capillary electrophoresis and automated florescence color readout. The
automated procedure saw great adoption in the vast majority of sequencing projects.
Although Sanger sequencing, and its derivative methods, has the disadvantage of
high cost and low throughput, it produces significant longer sequencing reads that is
essential for certain genomic applications (e.g. de novo assembly), and is often used as
a validation method to verify the genomic variations discovered through NGS technolo-
gies.
1.2.3 NEXT GENERATION SEQUENCING
Next generation sequencing is a collection of methods that increase the throughput
of traditional Sanger sequencing by simultaneously sequence several hundred millions
of DNA fragments in parallel, utilizing either cyclic reversible terminators (Illumina,
Helicos) to reversibly terminate the process of DNA polymerization followed by im-
age capturing, quantitatively detecting the release of the pyrophosphate released by
the incorporation of dNTP (Roche/454), or use ligation instead of nucleotide addition
(SOLiD).
There are generally four steps to generate NGS data: template preparation, sequenc-
ing, imaging and data analysis [55]. DNA fragments are either clonally amplified with
emPCR6 followed by fixation onto an amino-coated glass slide by chemical cross-link
6emulsion-based PCR
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(Life/APG SOLID) [56] or fixed onto glass slide first, and then followed by solid phase
amplification (Illumina). Either way, the procedure results in millions of spatially sep-
arated DNA molecule template clusters.
1.2.3.1 ILLUMINA
In the sequencing step of Illumina platform, fluorescent labeled dNTP, with chemical
modification on the 3’-OH group to inhibit further dNTP incorporation, are used to
proceed the DNA polymerization in single steps. Since four dNTPs are labeled with
different colors, the current nucleotide can be decided for every clonal template clus-
ter. A cleavage step is followed to remove the fluorescent group as well as the blocking
group at 3’ to enable further polymerization and sequencing [57]. In an ideal situa-
tion, all the templates in a clonal cluster should be sequenced in synchrony. However,
de-phasing will occur if more (leading-strand de-phasing) or less (lagging-strand de-
phasing) nucleotides are incorporated onto some of the templates and introduce noise
to the florescence signal. Such noise is used to calculate a probability (“base quality”)
that a specific base call is incorrect [55]. As a consequence, de-phasing will result in
limited read length due to the low quality bases aggregating at the 3’ end.
1.2.3.2 ROACH/454 PYROSEQUENCING
Pyrosequencing is another “sequence-by-synthesis” method that, instead of relying on
chain termination (Section 1.2.2, Sanger Sequencing), works by detecting the pyro-
phosphate (PPi) released during dNTP incorporation [58–60]. The experiment consists
of cycles that only one of the four dNTPs are added into the system. If the particular
dNTP is complementary incorporated onto the synthesizing strand, PPi will be released,
which is quantitatively converted to light signal through luciferase-catalyzed reaction,
allowing the system to determine the sequence.
454 Life Sciences, which has been acquired by Roach Diagnostics, developed a par-
11
allelized version utilizing the same principle as pyrosequencing, taking advantage of
emPCR to clonally amplify single DNA template within water droplets suspended in an
oil solution. These clonal colonies are then transferred onto plates with picoliter-volume
wells, and standard pyrosequencing is carried out within each well [61]
1.2.3.3 SOLID
With SOLiD sequencing strategy, the DNA sequences are not determined by single ad-
dition of nucleotide, but by ligation of a short DNA probe that recognizes 2 consecutive
bases on the template strand [56]. Different florescent colors are assigned to two bases
instead of one. The sequencing process consists of the incorporation of 8-mer florescent
labeled probes by DNA ligase with the first two bases complementary to the template
sequence, color imaging, cleavage of the last 3 bases of the 8-mer, and incorporation
of the next 8-mer. An entire cycle of such procedure will give raise to a color sequence
representing the base change of every 2 bases separated by 3 bases. To cover the entire
sequence, the procedure will need to be repeated 3 more times, each time with a +1
base shift. As a result, every base is interrogated twice, and SNV will be easy to identify
since substitution of one base will result in color changes of two consecutive positions.
Sequencing errors are also easier to identify due to the fact that color changes with
different inner bases are invalid.
1.3 NGS DATA PROCESSING AND VARIANT DISCOVERY
A common pattern of the current in-production NGS technologies is that they produce
giga base-pairs of genomic sequencing data, but each individual sequencing read is
relatively short [55]. Because the sequencing reads do not retail the knowledge as in
where in the genome did they originated from, a common practice is to map all the
reads to a reference genome scaffold to identify their location of origin. Heng et al.
[62] reviewed the latest software packages designed to tackle this issue, with various
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algorithmic approaches and adaptations to specific sequencing technologies.
Many types of genomic variations can then be identified from the alignments, either
by measuring the amount of reads covering a certain region (read coverage) to identify
CNV events [63–68], interrogating the raw sequences to discover SNV events [69, 70],
or utilizing properties of the alignment reads (e.g. fragment length or orientation with
paired-end reads) to uncover CNV and structural variations [66–68].
An important aspect of variant discovery regarding cancer samples is that, due to the
existence of normal tissue mix-in and intratumoral heterogeneity, certain assumptions
made for germline variation discovery may no longer hold true. For example, when only
normal tissue is concerned, the allele frequency (AF) of a mutant allele at a specific locus
is either 0% (when the subject does not have the variation), 50% (when the subject is
heterozygous mutant) or 100% (when the subject is homozygous mutant). As a result
of heterogeneity or copy number alteration, somatic events in cancer samples do not
follow this trimodal distribution necessarily [71–73]. Methods have been developed to
tailor for these specific conditions [74–81]. Xu et al. [82] reviewed the performance of
these methods, and Kim et al. [83] proposed a strategy of combining multiple tools to
increase overall call quality.
1.4 STUDIES REVEAL INTRA-TUMOR GENOMIC HETEROGENEITY
Cancer has been known to be heterogeneous long before the arrival of high throughput
genomic profiling methods [84–105]. NGS, and more recently single cell sequencing
(SCS), enabled the elucidation of subclone structure into unprecedented level. Here I
briefly summarize the latest studies, utilizing NGS on bulk sample or SCS, that identified
intratumoral heterogeneity in various types of cancer.
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1.4.1 STUDIES BASED ON NGS
1.4.1.1 MYELOMA
Three studies [106–108] performed genome-wide analysis for the clonal landscape rep-
resenting the heterogeneity in multiple myeloma (MM). Keats et al. [106] traced genetic
changes over the entire disease course in a high-risk patient at 7 time points and iden-
tified 2 competing subclones. A Vk*MYC transgenic mouse was used to model the
competition of these two subclones. An important lesson learned in this animal model
was that the eradication a sensitive clone will probably resulted in the dominance of the
other refractory clone. Thus the authors suggested that combination therapies targeting
all co-existing subclones in the tumor would be more beneficial than sequential single-
agent therapy. Egan et al. [107] performed whole genome sequencing on 4 time-points
samples over tumor progression: diagnosis, first relapse, second relapse and end-stage
secondary plasma cell leukemia (sPLC) in a t(4; 14) MM patient. Results showed that
diagnostic and second relapse clones shared most SNVs, while the first relapse and the
sPLC clones have some unique SNVs, which “suggested greater evolutionary divergence
over time and disease aggressiveness”. Walker et al. [108] compared a group of MM
patient samples with t(4; 14). Only 3% of mutations, including driver mutations in
RAS/MAPK pathway, were shared by both group and, in addition, RAS pathway muta-
tions were not always present in the dominant clone, but instead in minor subclones in
half of the samples.
Recently, two more studies looked at the heterogeneity of genomic evolution in MM
[109, 110]. Bolli et al. analyzed 84 myeloma samples by whole exome sequencing and
copy number profiling. Melchor et al. also used whole exome sequencing in addition
to single cell qPCR7. Both studies identified linear and branching phylogenies, which
contained 5 to 6 subclones. A very important observation was made that in some of the
7quantitative real time PCR
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parallel evolution situations, two subclones independently “activated the RAS/MAPK
pathway through RAS mutations”, which resulted in distinct subclonal lineages [110].
1.4.1.2 BREAST CANCER
Nik-Zainal et al. [111] applied novel algorithms developed by the same group to 21
breast tumors. Dominant subclonal linage (defined as more than 50% of tumor cells)
was observed in every tumor and authors reasoned that hundreds and thousands of mu-
tations were accumulated in one cell lineage before it expanded into the dominant sub-
clone with the acquisition of “driver mutations”. In another study, Shah et al. [112] dis-
covered, with 104 triple-negative breast cancer (TNBC) cases and deep re-sequencing of
2,414 somatic mutations, that TNBC clonal structures vary drastically from case to case,
and concluded that “understanding the biology and therapeutic responses of patients
with TNBC will require the determination of individual tumor clonal genotypes”.
1.4.1.3 LEUKEMIA
Relapse caused the death of most acute myeloid leukemia (AML) patients [113]. By
comparing of genomes from primary tumor and relapse, two main clonal evolution
patterns were associated with relapse: either the major primary clones, or a minor
surviving subclone in primary from initial chemotherapy gained mutations and evolved
into the relapse [113]. Another group independently investigated clonal evolution of
preleukemic hematopoietic stem cells (HSCs). By using targeted exome sequencing, Jan
et al. [114] identified cellular and genomic path from HSCs to the dominant presenting
leukemic clone.
1.4.1.4 CHRONIC LYMPHOCYTIC LEUKEMIA
Schuh et al. [115] monitored the disease progression in 3 CLL patients by sampling at
5 time points over up to 7 years. Whole genome sequencing results on the collected
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samples showed that each sample had up to 5 distinct subpopulations. The mutation
profiles at different time points revealed the clonal evolution process, which was rep-
resented by the dynamics of subclones that declined or expanded over time.
Another intratumoral heterogeneity study was conducted by Landau et al. in 149 CLL
cases [73]. Cell frequencies of somatic mutations were generated from whole exome
sequencing and copy number analysis. Some driver mutations, such as MYD88, trisomy8
12 and del(13q) were found to be predominantly clonal, signaling early acquisition,
whereas others such as SF3B1 and TP53 were found to be subclonal, representing later
events.
1.4.1.5 MYELOPROLIFERATIVE NEOPLASMS
Lundberg et al. [116] did comprehensive analysis in a cohort of 197 myeloproliferative
neoplasm (MPN) patients by targeted NGS of 104 genes. A strong correlation was
found between the total number of somatic mutations and survival and risk of leukemia
transformation. Clonal analysis was carried out by genotyping DNA from signal colonies
grown in methylellulose and genes focused in this study were epigenetic modifiers.
Mutation profiles of TET2, DNMT3A, JAK2, V617F, ASXL1, EZH2, and IDH1 revealed 8
types of clonal structures.
1.4.1.6 MANTLE CELL LYMPHOMA
Beá et al. [117] reported a whole genome and/or exome sequencing study on 29 MCL
and normal tissue pairs, and identified some recurrent mutations which then were in-
vestigated by targeted NGS in an independent 172 MCL cases. Sequencing data of two
tumor samples were obtained from two different topographic sites or at two time points
from each patient were used to establish 4 types of subclonal architectures in MCL.
8having three instances of a particular chromosome, instead of the normal two
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1.4.1.7 RENAL CARCINOMAS
Gerlinger et al. [118] performed exome sequencing, chromosome aberration analysis,
and ploidy9 profiling on “multiple spatially separated” primary and associated metastatic
renal carcinoma samples, and revealed branching evolution pattern in tumor growth.
Tumor suppressor genes, such as SETD2, PTEN, and KDM5C exhibited convergence
evolution, “underwent multiple distinct and spatially separated inactivating mutations
within a single tumor”. Ploidy heterogeneity was also observed in two of four tumors.
1.4.1.8 PANCREATIC CANCER
Yachida et al. [119] carried out genomic sequencing of primary and metastatic cancers
to assess their clonal relationships in 7 pancreatic cancer patients. They found that dis-
tant metastasis clones were originally within the primary carcinoma, which were non-
metastatic clones. The authors also generated a time-line of metastasis initiation and
occurring that at least 10 years for the tumor initiation, 5 years for the arise of parental
metastatic clones, and then about 2 more years till decease. Another study was con-
ducted by Compbell et al. [120] with parallel paired-end sequencing on 13 pancreatic
adenocarcinoma patients. Besides identifying somatic mutations and rearrangements,
they also investigated phylogenetic relationships, and confirmed that certain clones in
the primary tumor had the ability to initiate metastasis. In addition, they discovered
that organ-specific branching patterns of phylogenetic trees. The authors suggested
two explanations: particular genotypes might drive metastasis to a particular organ; or,
metastatic clones may expand in a stepwise process.
9The number of copies of a complete genome in a cell. Normal cells have two copies, thus diploid.
Tumor cells with copy number variation could potentially contain three copies, or triploid, or more.
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1.4.2 STUDIES BASED ON SINGLE CELL SEQUENCING
1.4.2.1 BREAST CANCER
A method of combining flow-sorted nuclei, whole genome amplification, and NGS was
able to accurately quantify genomic copy number changes within an individual nucleus
[121]. By utilizing this method, Zik-Zainal et al. analyzed two sets of 100 single cells,
and identified three distinct clonal subpopulations in a poly-genomic tumor and a single
clonal expansion forming the primary tumor and seeded the metastasis in a mono-
genomic primary tumor and its liver metastasis [121].
1.4.2.2 MYELOPROLIFERATIVE NEOPLASMS
A high-throughput whole genome single cell sequencing method was developed by Hou
et al. [122]. This method was of high sensitivity and had a distinct genomic distribution
from tissue sequencing that GC extremely enriched regions had lower amplification ef-
ficiency. This method was used to sequence 90 cells from a JAK2-negative MPN patient,
and identified a monoclonal evolution pattern in this patient sample.
1.5 CHALLENGES
As it was made clear by the studies mentioned above, tumor samples are highly hetero-
geneous in terms of the genomic profiles of the constituting cancer cells. The hetero-
geneity itself contributes to the complexity of tumor genome, and hinders the investiga-
tion of mechanisms, such as tumorigenesis or metastasis, through traditional means. To
make things worse, the problem of delineating each individual genomic profile within
a tumor mass is fundamentally different from phylogenetic tree constructing since each
individual genome cannot be observed separately. Thus it calls for novel computational
methods to elucidate the number of different genomes, and their specific profiles, from
various signals that represent the mixture of them all.
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2
Linear evolution model
O
NE OF THE CHALLENGES in analyzing cancer sequencing data was that the
tumor sample used for sequencing would often have normal cells mixed
in, or “normal contamination”. For example, when a tumor is surgically
removed, the surgeon will also remove the surrounding normal tissues as well to ensure
maximum removal of tumor cells. Macrophage invasion and blood can also be sources
for normal contamination. We started to design computational methods to estimate
the level of contamination by looking for signals that separate the normal “clone” that
all share the germline genome from tumor clone that all have the mutated somatic
genome. Soon, however, we realized that the clonal structure is far more complex than
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this binary segregation.
2.1 TUMOR IS HETEROGENEOUS
As part of a collaboration with Baylor College of Medicine, we gained access to the
The Cancer Genome Atlas (TCGA) Ovarian Cancer dataset primary alignment data in
the format of BAM1 files. Although many studies had been published on the topic of
estimating normal contamination, as well as extracting Copy Number Variation (CNV)
features, with Single Nucleotide Polymorphism (SNP) array data [123–130], only a few
methods were able to utilize Next Generation Sequencing (NGS) data [131–133], and
none of which was considering normal contamination. We performed our own copy
number analysis procedure on whole genome sequencing samples that consisted of the
following steps to estimate normal contamination:
1. The read depth (RD), number of sequencing reads starting within a region, was
scanned through the entire genome by a 10kb non-overlapping moving window
(Figure 2.1.1 A, B).
2. The read depth in normal and tumor were separately normalized by the total
number of reads in each sample.
3. The read depth ratio (RDR), with the definition that RDR = RDTRDN , was calculated
for every corresponding window, and a histogram was generated (Figure 2.1.1
C). This step also effectively filtered out any germline (inherited) events to allow
the subsequent steps to only consider somatic (acquired) events.
4. The histogram envelope signal was extracted using Fast Fourier Transform (FFT),
and low pass filtered to reduce high frequency noises (Figure 2.1.2 A, B, note that
the sample is different from Figure 2.1.1).
1A binary file format widely used for storing sequencing reads alignments.
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Figure 2.1.1: The procedure to calculate read depth ratio, RDR, from paired tumor-normal
samples. A) Read depth measured in a 10kb moving window on the whole genome sequenc-
ing data of patient TCGA-06-0152 primary tumor sample. B) Read depth measured in a 10kb
moving window on the whole genome sequencing data of patient TCGA-06-0152 normal sam-
ple. C) Read depth ratio between the tumor and normal sample of patient TCGA-06-0152.
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Figure 2.1.2: The procedure to estimate. A) The histogram of RDR. Peak shape is very ob-
vious B) FFT de-noised histogram envelope. Black line represents identified copy number 2
peak, while blue line represents identified copy number 1 peak. Based on these two lines, lo-
cation of copy number 3 and 4 are estimated with the knowledge of contamination (red and
dark red lines). C) Plot of RDR along chromosome locations with identified and estimated
ratio of specific copy numbers drawn as horizontal lines (definition is the same as in B)
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5. Global maximum was identified and assumed to be copy number 2 with corre-
sponding ratio denoted as R2 (Figure 2.1.2 B, black line).
6. The first local maximum on the left side of R2 was identified, and assumed to
be copy number 1 and denoted as R1 (Figure 2.1.2 B, blue line). In a simple
model where only two genomes, tumor and mixed-in normal, are considered, the
contamination level α could then be estimated by these two values
1× (1−α) + 2×α
2
=
R1
R2
α= 2× R1
R2
− 1 (2.1)
7. With α estimated, the corresponding RDR of copy number 3,4, . . . , n can be cal-
culated with Equation 2.2 (Figure 2.1.2 B, red and dark red lines).
Rn
R2
= [n(1−α) + 2α]/2 (2.2)
As shown in Figure 2.1.2 this approach worked relatively well within the boundary
of a single chromosome for the specific individual TCGA-04-1371. Using the estimated
contamination level α, the RD peak for copy number 3 and 4 were predicted accurately.
However, once we looked at all the chromosomes in the entire genome, it turned out
that different chromosome resulted in different α estimation (Figure 2.1.3 A). This did
not make sense because the normal contamination should reflect the amount of nor-
mal cell mixed within the tumor sample, which should be identical across the entire
genome. More interestingly, the estimated α values for all the chromosomes seemed to
cluster into three distinct groups. The only way to rationalize the observation was that
(Figure 2.1.3 B)
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Figure 2.1.3: Normal contamination estimation based on all chromosomes in the pri-
mary tumor sample in patient TCGA-04-1371, and its parsimonious subclone structure.
A) The estimation values from different chromosomes are grouping into three clusters, with
α = 0.2,0.5, and 0.8 respectively. B) The parsimonious subclone structure that explains the
data. The events that resulted in lower α estimation, which represents higher tumor purity,
exist in more subclones.
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• The tumor cells, instead of sharing the same genome, actually were comprised of
different subgroups, or subclones.
• The cells within the same subclone share the same genome.
• Genomic variations exist in at least one, but possibly more subclones. The sub-
groups which do not contain a specific variation would “act” like normal cells,
and contribute to the estimated α, at the location of that variation.
2.2 PARSIMONIOUS SOLUTION BASED ON LINEAR EVOLUTION MODEL
Based on the observation we made in Section 2.1, we rationalized that, one way to
model the multi-level α estimation based on the copy number data is that, for n different
levels of distinct α, there exist at least n tumor subclones (hence parsimonious) plus 1
contaminating normal clone. The tumor subclones follow a linear evolutionary model,
in which the events resulting in the lowestα estimation emerged in tumor tissue cells the
earliest, and expanded into the initial tumor subclone population. One of the cell in the
tumor population further gained mutations, and developed into another subpopulation.
But because the events acquired later only exist in a subset of the entire tumor sample,
when being interrogated alone, they will result in a higher α estimation because more
cells (normal tissue plus those tumor cells that contain the initial events, but not the
later events) would appear to be normal tissue at those specific genomic locations. New
subclone always emerges from the most mutated, existing subclone, inheriting all the
existing events, and in addition contain their own set of events.
We then developed an algorithmic procedure to reconstruct the parsimonious sub-
clone structure based on this model, to which the input is a list of CNV events, and
their associated RDR. The somatic RDR is then converted to Cell Prevalence (CP), that
describes the fraction of cells in the sequenced tumor sample that harbors a particular
event. In order to be able to compute CP, the absolute copy number (ACN) state of
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an event, i.e. the exact number of copy of DNA at the location of the event, is neces-
sary, which is often a non-trivial task to estimate. We estimate the ACN assuming that
CP follows a Uniform Distribution U(0,1), using a Maximum Likelihood method that
L (RDR|ACN) is maximized. Given an overall ploidy2 p, which can be estimated by
methods such as ASCAT [134] and ABSOLUTE[135], or assumed to be 2 if no other
information is available, the method will result in a closed form:
ACN = argmax
i
i
p
< RDR, i = 0,1, . . . (2.3)
The method can be implemented in a iterative fashion in the following steps (Fig-
ure 2.2.1)
1. Initialize the subclone structure with a single subclone that represents the normal
tissue mixture. This subclone contains no event, and its frequency f = 1
2. Identify the events in the event list that have the lowest C P = C P ′; create a new
subclone which contains all the events in the event list; set its frequency f = C P ′,
and subtract C P ′ from the frequency of the “normal” clone; remove the events
considered in this step from the event list; subtract the C P of all the events in the
event list by C P ′
3. If the event list still has events in it, repeat step 2; Otherwise, return the subclone
structure
Formally, the method is designed on the following definitions:
Definition 2.1. A chromosomal location, L, is defined as L = {chromosome, position},
which describes a location on the genome.
Definition 2.2. A chromosomal segment, S, is defined as S = {L, length}, which describes
a continuous region on the genome.
2The number of copies of a complete genome in a cell. Normal cells have two copies, thus diploid.
Tumor cells with copy number variation could potentially contain three copies, or triploid, or more.
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Definition 2.3. S contains L iff L.chromosome = S.L.chromosome, L.position≥ S.L.position,
and L.position< S.L.position+ S.L.length. We denote this as L ∈ S
Definition 2.4. Two chromosomal segments, S and S′, overlaps iff S′.L ∈ S, assuming
without loss of generality that S.L.position≤ S′.L.position
Definition 2.5. A segmental somatic CNV event (henceforth referred to as “event” if with-
out specification), e, is defined as e = {S, ACN} for a segment on the genome specified by
S, with the absolute copy number state of ACN.
Definition 2.6. An observed somatic CNV event (henceforth referred to as “observed event”
if without specification), oe, is defined as oe = {e, C P} for an event e observed in C P > εd
fraction of the total cells, with some detection sensitivity εd > 0.
Definition 2.7. An observation, O, is defined as O = {oe1, oe2, . . . , oen} for a segmented
tumor genome profile with n segments of non-modal RDR (The following discussion assume
a modal copy number being 2, thus a modal RDR = 1). The chromosomal segments, S,
of the events, e, in oei and oei+1 need not be continuous, since locations of the genome
can potentially be masked out. Observed events are identified with genomic segmentation
algorithms, which will result in non-overlapping segments.
Definition 2.8. The complete events set, E, is defined as E = {oe.e|oe ∈ O}.
Lemma 2.1. For any given genomic location L, there exist at most 1 observed event oe so
that L ∈ oe.e.S
Proof. Suppose that, for a given L, there exist two observed events oe and oe′, so that
L ∈ oe.e.S and L ∈ oe′.e.S. We denote, for simplicity, oe.e.S as S and oe′.e.S as S′. We
also assume, without loss of generality, that S′.L.position≥ S.L.position
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L ∈ S′ =⇒ L.pos ≥ S′.L.pos
L ∈ S =⇒ L.pos < S.L.pos + S.length
=⇒ S′.L.pos < S.L.pos + S.length
combined with the assumption that S′.L.position≥ S.L.position
=⇒ S′.L ∈ S
=⇒ S and S′overlaps
This contradicts with Definition 2.7
Corollary 2.1. For any given genomic location L, there exist at most 1 event e ∈ E so that
L ∈ e.S.
Proof. Suppose that, for a given L, there exist two events e ∈ E and e′ ∈ E, so that
L ∈ e.S and L ∈ e′.S. Due to Definition 2.8, there must exist two observed events
oe ∈ O ∧ oe.e = e =⇒ L ∈ oe.e.S and oe′ ∈ O ∧ oe′.e = e =⇒ L ∈ oe′.e.S. This
contradicts with Lemma 2.1
Definition 2.9. A subclone profile, C, is defined as C j = {G, f } j, j = 0..m, f ≥ 0, in which
C j.G ⊆ E is a set of events the j-th subclone contains. The 0-th subclone is a special one
representing the normal tissue component, thus C0.G = {}. C j. f represents the fraction
the j-th subclone occupies over the entire cell population, or subclone frequency (SF), and
that
∑m
j=0 C
j. f = 1
Definition 2.10. An actual (observed) genomic profile, A, is defined as A = {Al}, l =
1,2, . . . for each unique location Ll on the genome. Since at most 1 oe exists so that
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Ll ∈ oe.e.S (Lemma 2.1), Al is calculated as following
Al =

oe.e.ACN
2
× oe.C P + (1− oe.C P) ∃!oe ∈ O : Ll ∈ oe.e.S
1 otherwise
which can be simplified as
Al =

1+
oe.e.ACN − 2
2
× oe.C P ∃!oe ∈ O : Ll ∈ oe.e.S
1 otherwise
(2.4)
Definition 2.11. A model genomic profile, M, is defined as M = {Ml}, l = 1,2, . . . for
each unique location Ll on the genome. Since for any given subclone C
j, at most 1 e exists
for C j.G so that Ll ∈ e.S (Corollary 2.1), Ml is calculated as following
Ml =
m∑
j=0

e.ACN
2
× C j. f ∃!e ∈ C j.G : Ll ∈ e.S
1× C j. f otherwise
(2.5)
Definition 2.12. A model fitness score, f i t, is defined as in Equation 2.6, which calculates
the difference between the model and actual genomic profiles.
f i t =
genomic length∑
l=1
|Ml − Al | (2.6)
Definition 2.13. If, in a given subclone profile C with m+1 subclones, the condition that
∀ j < m : C j.G ⊆ C j+1.G is satisfied, the subclone profile is said to be according to a linear
evolution model. We say that a profile is parsimonious when the following conditions are
met
∀ j < m : C j.G ⊂ C j+1.G
∀ j ∈ [1, m] : C j. f > ε f for a given error margin ε f ≥ 0
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Definition 2.14. The problem of subclone structure reconstruction with linear evolution
model, is that given an observation O, find a subclone profile C, in which C j.G ⊂ C j+1.G, j =
0..m− 1, that minimizes f i t. We say that a subclone profile C is a solution to an obser-
vation O if, for a given error margin ε f i t ≥ 0, f i t ≤ ε f i t .
Theorem 2.1. For any given subclone structure C that is a solution to an observation O
and the implied complete event set E
m⋃
j=1
C j.G = E
Proof. Assume that
m⋃
j=1
C j.G = E′ 6= E
Due to the fact that ∀ j ≤ m : C j.G ⊆ E (Definition 2.9), we have
E′ ⊂ E
=⇒∃e ∈ E : e 6∈ E′
=⇒∀Ll ∈ e.S : Ml = 1 (Equation 2.5)
yet
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e ∈ E
=⇒∃oe ∈ O : oe.e = e
=⇒∀Ll ∈ e.S : Al = 1+ oe.e.ACN − 22 × oe.C P (Equation 2.4)
=⇒∀Ll ∈ e.S : |Ml − Al |= |1− (1+ oe.e.ACN − 22 × oe.C P)|
=⇒ f i t ≥ |2− oe.e.ACN
2
× oe.C P| × e.S.length (Equation 2.6)
thus, for any given ε f i t < |2−oe.e.ACN2 × oe.C P| × e.S.length, C cannot be a solution to
the observation O, contradicting with the starting condition.
Theorem 2.2. For any parsimonious linear subclone profile (Definition 2.13) C with m+1
subclones that is also a solution to an observation O with n observed events, m≤ n
Proof. Note that O is with n observed events implies that E is with n events (Defini-
tion 2.8). Assume that m> n, because C is parsimonious,
∀ j < m : C j.G ⊂ C j+1.G
=⇒ |C j+1.G|> |C j.G|
=⇒ ∀ j ≤ m : |C j.G| ≥ j
=⇒ ∀ j that m≥ j > n : |C j.G| ≥ j > n
This contradicts with Definition 2.9, that ∀ j ≤ m : C j.G ⊆ E.
Definition 2.15. A set of event clusters, P, is defined as a partition over an observation
O, that, for a given error margin εP ≥ 0, satisfies
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∀p ∈ P :(∀oe ∈ p, oe′ ∈ p : |oe.C P − oe′.C P| ≤ εP)
and
∀p ∈ P, p′ ∈ P, p 6= p′ :(∀oe ∈ p, oe′ ∈ p′ : |oe.C P − oe′.C P|> εP)
Each element p ∈ P is called an event cluster. We denote p.C P =
∑
oe∈p
oe.C P
|p| as the
cluster centroid.
We further impose, without loss of generality, that P is a sorted set, with respect to the
cluster centroids, in descending order.
∀i ∈ [1, n′], j ∈ [1, n′], i < j : pi.C P > p j.C P
Theorem 2.3. For any parsimonious linear subclone profile (Definition 2.13) C with m+1
subclones that is a solution to an observation O with n observed events being partitioned
as P with n′ ≤ n clusters, m≤ n′
Proof. P is a partition over O =⇒ |P| ≤ |O|.
If |P| = |O| =⇒ n′ = n, with Theorem 2.2, we have m ≤ n′; otherwise (|P| < |O|),
assume that m> n′
m⋃
j=1
C j.G = E (Theorem 2.1)
⇒|
m⋃
j=1
C j.G|> |P|
32
Due to pigeonhole principle,
∃p ∈ P, |p|> 1 : {
∃ j ≤ m, j′ ≤ m, 0< j < j′ : [
∃oe.e ∈ C j.G, oe′.e ∈ (C j′ .G − C j.G) : oe ∈ p ∧ oe′ ∈ p
]}
Let
foe =
m∑
k= j
C k. f
foe′ =
m∑
k= j′
C k. f
Thus we have
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oe ∈ C j.G ∧ oe ∈ C j′ .G
oe′ 6∈ C j.G ∧ oe′ ∈ C j′ .G
=⇒
∀Ll ∈ oe.e.S : |Ml − Al |
= |(
j−1∑
k=0
C k. f +
m∑
k= j
oe.e.ACN
2
× C k. f )− (1+ oe.e.ACN − 2
2
× oe.C P)|
= |(1− foe) + oe.e.ACN2 × ( foe − oe.C P)− (1− oe.C P)
= |(oe.e.ACN
2
− 1)× ( foe − oe.C P)| (2.7)
∀Ll ′ ∈ oe′.e.S : |Ml ′ − Al ′ |
= |(
j′−1∑
k=0
C k. f +
m∑
k= j′
oe′.e.ACN
2
× C k. f )− (1+ oe′.e.ACN − 2
2
× oe′.C P)|
= |(1− foe′) + oe
′.e.ACN
2
× ( foe′ − oe′.C P)− (1− oe′.C P)
= |(oe′.e.ACN
2
− 1)× ( foe′ − oe′.C P)| (2.8)
Assume that, at all other genomic locations, |M−A|= 0, for some small value ε1 ≥ 0,
the following conditions must hold
|oe.e.ACN
2
− 1| × | foe − oe.C P|< ε1
|oe′.e.ACN
2
− 1| × | foe′ − oe′.C P|< ε1
in order for C to be a solution of O, with ε f i t > (oe.e.S.length+ oe′.e.S.length)× ε1.
Because ∀oe : oe.e.ACN ∈ N ∧ oe.e.ACN 6= 2 (Definition 2.7), | oe.e.ACN2 − 1| ≥ 0.5, the
above can be rewritten, with ε′ = 2ε1, as
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| foe − oe.C P|< ε′
| foe′ − oe′.C P|< ε′
combined with the fact that |oe.C P − oe′.C P| < εP , under the worst case scenario
that foe > oe.C P, oe.C P > oe
′.C P, and foe′ < oe′.C P, with ε1 > εP , we have
foe − oe.C P < ε′
oe′.C P − foe′ < ε′
oe.C P − oe′.C P < ε′
when added together, we have
foe − foe′ < 3ε′
Recall that
foe =
m∑
k= j
C k. f
foe′ =
m∑
k= j′
C k. f
0< j < j′ ≤ m
We have
j′−1∑
k= j
C k. f < 3ε′
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However, this cannot be by Definition 2.13, when ε f ≥ 3j′− jε′.
Theorem 2.4. For any parsimonious linear subclone profile (Definition 2.13) C with m+1
subclones that is a solution to an observation O with n observed events being partitioned
as P with n′ ≤ n clusters, m≥ n′
Proof. Assuming that there exists one subclone profile C with m < n′ that is a solution
to O, due to pigeonhole principle, ∃p ∈ P, p′ ∈ P,∃ j ≤ m,∃oe ∈ p, oe′ ∈ p′, that
oe.e 6∈ C j−1.G ∧ oe′.e 6∈ C j−1.G
oe.e ∈ C j.G ∧ oe′.e ∈ C j.G
Similar to the proof of Theorem 2.3, if we let
foe =
m∑
k= j
C k. f
foe′ = foe
we have
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∀Ll ∈ oe.e.S : |Ml − Al |
= |(oe.e.ACN
2
− 1)× ( foe − oe.C P)| (2.9)
∀Ll ′ ∈ oe′.e.S : |Ml ′ − Al ′ |
= |(oe′.e.ACN
2
− 1)× ( foe′ − oe′.C P)|
= |(oe′.e.ACN
2
− 1)× ( foe − oe′.C P)| (2.10)
Assume that, at all other genomic locations, |M−A|= 0, for some small value ε2 ≥ 0,
the following conditions must hold
|oe.e.ACN
2
− 1| × | foe − oe.C P|< ε2
|oe′.e.ACN
2
− 1| × | foe − oe′.C P|< ε2
in order for C to be a solution of O, with ε f i t > (oe.e.S.length+ oe′.e.S.length)× ε2.
Because ∀oe : oe.e.ACN ∈ N ∧ oe.e.ACN 6= 2 (Definition 2.7), | oe.e.ACN2 − 1| ≥ 0.5, the
above can be rewritten, with ε′ = 2ε2, as
| foe − oe.C P|< ε′
| foe − oe′.C P|< ε′
under the worst case scenario that foe > oe.C P, foe < oe
′.C P, with ε2 < 14εP , we have
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foe − oe.C P < ε′
oe′.C P − foe < ε′
when added together, we have
oe′.C P − oe.C P < 2ε′ < 4ε2 < εP
However this contradicts with Definition 2.15, that
∀p ∈ P, p′ ∈ P, p 6= p′ : (∀oe ∈ p, oe′ ∈ p′ : |oe.C P − oe′.C P|> εP)
Corollary 2.2. If there exists a parsimonious, linear subclone profile C, which is also a
solution to an observation O with a clustering partition P having n′ clusters, there are ex-
actly n′+1 subclones in C (Theorem 2.3 and Theorem 2.4) with the following relationships
among the error margins, for some constant C1 > 0, C2 > 0, C3 > 0 and some small value
ε1 ≥ 0,ε2 ≥ 0
C1ε f i t > ε1
C2ε f i t > ε2
C3ε f > ε1
ε1 > εp > 4ε2
Theorem 2.5. A parsimonious, linear subclone profile C with exactly n′+1 subclones that
is a solution to an observation O with a clustering partition P having n′ clusters always
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exists, and can be constructed as the following
∀ j ≤ n′ : C j.G =

{} j = 0
{oe.e|oe ∈⋃ ji=1 pi} otherwise (2.11)
∀ j ≤ n′ : C j. f =

1− p1.C P j = 0
p j.C P − p j+1.C P 0< j < n′
p j.C P j = n′
(2.12)
We then prove that the subclone profile C is linear, parsimonious, and a solution to O.
Proof. C is linear
∀ j < n′ : C j.G = {oe.e|oe ∈
j⋃
i=1
pi}, C j+1.G = {oe.e|oe ∈
j+1⋃
i=1
pi}
=⇒ C j+1.G − C j.G = {oe.e|oe ∈ pi+1}
∵P is a partition over O
∴pi+1 6= ;
=⇒ C j.G ⊂ C j+1.G (2.13)
=⇒ C j.G ⊆ C j+1.G
Proof. C is parsimonious
∀ j < n′ : C j.G ⊂ C j+1.G has already been proven by Equation 2.13.
When j = n′, C j. f = p j.C P > εd (Definition 2.6);
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When 0< j < n′,
C j. f = p j.C P − p j+1.C P
> εp (Definition 2.15)
Thus ∀ j ∈ [1, n′] : C j. f > ε f as long as ε f <min(εd ,εp)
Proof. C is a solution to the observation O.
∀Ll over the entire genome, one of the two following things can happen
• ∀oe ∈ O : Ll 6∈ oe.e.S (case 1)
• ∃oe ∈ O : Ll ∈ oe.e.S (case 2)
In case 1, Ml =
∑n′
j=0 C
j. f = 1 (Definition 2.9); Al = 1 (Equation 2.4); |Ml − Al | =
0≤ ε f i t for any ε≤ 0.
In case 2, ∃! j ≤ n′ : oe ∈ p j =⇒ oe.e ∈ C j.G, C j+1.G, . . . , Cn′ .G.
Ml =
j−1∑
k=0
1× C k. f +
n′∑
k= j
oe.e.ACN
2
× C k. f
= (1−
n′∑
k= j
C k. f ) +
oe.e.ACN
2
×
n′∑
k= j
C k. f
Al =
oe.e.ACN
2
× oe.C P + (1− oe.C P)
= (1− oe.C P) + oe.e.ACN
2
× oe.C P
Consequently
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|Ml − Al |= |(oe.e.ACN2 − 1)× [
n′∑
k= j
C k. f − oe.C P]|
= |(oe.e.ACN
2
− 1)| × |
n′∑
k= j
C k. f − oe.C P|
Because
n′∑
k= j
C k. f =(p j.C P − p j+1.C P)
+ (p j+1.C P − p j+2.C P)
+ · · ·
+ (pn′−1.C P − pn′ .C P) + pn′ .C P
=pk.C P
We have
|Ml − Al |= |(oe.e.ACN2 − 1)| × |p j.C P − oe.C P|
Combine case 1 and case 2 together, over the entire genome, we have
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f i t =
genome length∑
l
|Ml − Al |
=
n∑
i=1
[oei.e.S.length× |(oei.e.ACN2 − 1)| × |pi′ .C P − oei.C P|] (in which oei ∈ pi′)
≤
n∑
i=1
[oei.e.S.length× |(oei.e.ACN2 − 1)| × ε3]
in which ε3 ≥ 0 is the largest difference between any cluster centroid and the CP
value of their member observed events, or, formally
∀p ∈ P : ∀oe ∈ p : ε3 ≥ |p.C P − oe.C P|
∴ for any ε f i t ≥
n∑
i=1
[oei.e.S.length× |(oei.e.ACN2 −1)| ×ε3], we have f i t ≤ ε f i t .
The method, which is outlined in Listing 2.1, implements Equation 2.11 and Equa-
tion 2.12 described in Theorem 2.5, albeit starting with the event cluster that has the
lowest cluster centroid. It modifies P and O so that the SF of the newly introduced sub-
clone is always determined by the third case in Equation 2.12. A toy example is shown
in Figure 2.2.1, in which those nodes that have a genotype and frequency label besides
them are the subclones in the model.
2.3 ANALYSIS OF OVARIAN SERIOUS CARCINOMA COPY NUMBER VARIA-
TION DATASET
2.3.1 INTRODUCTION
High grade serous ovarian cancer is a highly aggressive and lethal disease. While most
patients achieve an initial clinical remission, approximately 80% of patients recur within
a five year period. Continuing advancements in sequencing technologies allow stud-
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Input: P = P[1], P[2], ..., P[n’]
Input: O = O[1], O[2], ..., O[n]
Initialize C with one subclone , C[0]
C[0].f = 1; C[0].G = {}
for i = n’ .. 1 :
newC.f = P[i].CP
newC.G = { oe.e for oe in O }
C[0].f -= newC.f
insert newC after C[0]
// update P and O due to the introduction of newC
P = P - {P[i]}
n’--
for j = 1 .. n’ :
P[j].CP -= newC.f
end -for
O = O - {oe for oe in P[i]}
n = n - size(P[i])
for j = 1 .. n :
O[i].CP -= newC.f
end -for
end -for
Listing 2.1: Pseudo code of the linear model algorithm.
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Figure 2.2.1: Illustration of the parsimonious method to reconstruct the subclone structure
with a linear heritage model. New subclones are introduced into the model stepwise, each
time explaining the least prevalent events completely, until the observation (actual) can be
entirely explained by the model.
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ies of the tumor genome in ever increasing detail. Improving knowledge on intratu-
moral heterogeneity and the identification of the clonal structure of tumor samples, by
sequencing of single cells or sequencing of tumors at very high coverage levels, may
provide important new insights into mechanisms of tumor evolution and progression
[89, 121, 136, 137].
To gain insight into the mechanisms used by tumor cells to evade the cytotoxic effects
of chemotherapy, and taking advantage of the highly standardized nature of treatment
regimens for ovarian serous carcinoma, we participated in a joint effort to characterize
the genomes of the primary and relapse tumors of seventeen patients with ovarian car-
cinoma, using a combination of whole genome sequencing, whole exome sequencing,
DNA copy number, methylation and gene expression profile. We applied the method
described in Section 2.2 in an attempt to provide insights into the mechanism of tumor
relapse in ovarian cancer.
Please refer to Table 4.0.1 for a summary of input data types and major conclusions.
2.3.2 RESULTS
2.3.2.1 CLONAL STRUCTURE RECONSTRUCTION
First, we used the precise and linear measurements of copy number level established
by whole genome sequencing to reconstruct each of the ten whole gnome samples into
a set of subclones. Next we assessed the distance between each primary and matching
relapse subclone to derive a model of tumor progression in each patient.
To establish the clonal structure of a tumor sample, we removed all loci of copy num-
ber gain, and kept only segments with equal to or less than the modal copy number.
Next, all remaining copy number segments were clustered into discrete levels, with the
requirement for each cluster to contain DNA segments covering at least 10 mega-bases.
In a simplified model of a diploid4 tumor genome, three possible ACN categories exist
4Having two copies of the complete genome.
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A 
B 
C 
D 
Figure 2.3.1: Inferring subclones through clustering of copy number levels. A) Whole
genome copy number profile is quantified by calculating, for each 10kb non-overlapping mov-
ing window, the log 2 ratio of the number of reads initiating within a specific window (RD) in
the tumor sample relative to the read depth in the paired-normal sample. B) The log 2 ratio
is subjected to circular binary segmentation [138] for identifying continuous regions with the
same underlying copy number state. C) The identified segments are clustered to find discrete
levels. D) A parsimonious subclone structure is generated with a biologically motivated model
that late subclones inherited the mutations existed in earlier subclones. Blue regions represent
heterozygous deletion.
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A 
B 
Figure 2.3.2: Schematic representation of clonal evolution in a single primary-relapse tu-
mor pair. A) The development of primary and relapse tumor from the cell of origin is depicted
over time. Using copy number levels inferred from whole genome sequencing data, four sub-
clonal populations were predicted to be present at time of diagnosis. One of the subclones
was found in the relapse tumor, combined with two new clones that were derived from an
ancestral tumor cell population that was too small to be detected in the primary tumor. The
percentages (in white) reflect the fraction of tumor cells for each subclone. B) Using copy
number levels obtained from the Agilent3 1M platform, three subclones were found in the pri-
mary tumor. One subclonal population was found again in the relapse tumor, while two novel
subclones developed from ancestral cells. The percentages (in white) reflect the fraction of
tumor cells for each subclone.
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after removal of all chromosomal regions of copy number gain: 1. Diploid / wild-type;
2. Heterozygous loss; 3. Homozygous loss. Any levels deviating from this model were
likely resulted from the presence of copy number alterations in subclonal tumor cell
populations. We obtained tumor purity and tumor ploidy of all samples using ASCAT
[134] with microarray CNV data and default parameters. Using the whole genome se-
quencing derived segmented copy number data from the primary tumor sample of pa-
tient TCGA-29-1707, we inferred the presence of five copy number level clusters, which
are explained by four tumor subclones and one normal tissue component. Similarly, we
found three clones in the TCGA-29-1707 relapse tumor (Figure 2.3.1, Figure 2.3.2 A).
Next, a distance matrix of all possible primary-relapse clone pairs was generated, using
Pearson correlation as a distance metric, to establish the evolutionary trajectory from
primary tumor to regrowth (data not shown). Genome correlation was assessed by
comparing absolute levels of gains and losses across the entire genome. In the example
TCGA 29-1707, a subset of copy number levels and alterations were found in all clones
suggesting that all primary and relapse clones were derived from a common ancestor
cell. Two clones in the relapse sample lacked copy number changes found in all primary
clones, and must therefore originate from an ancestral tumor cell that was present in the
primary tumor but at levels that we were unable to detect. The third relapse subclone
harbored alterations also found in the first primary clone, but not other primary clones,
and we therefore suggest that the first primary subclone is the founder population that
gave rise to the third relapse subclone.
Using whole genome sequencing of primary and relapse tumor pairs, the tumor
progression structure of two additional ovarian carcinomas was reconstructed (Fig-
ure 2.3.3). Of note, a substantial fraction of ovarian cancer is thought to harbor highly
aneuploid5 genomes, resulting in a modal number of chromosomes of three or higher
[134, 135]. We predicted tumor ploidy for each sample using ASCAT [134] and ac-
5Having a ploidy that is other than 2
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counted for triploid6 genomes by allowing the cluster structure to contain three pos-
sible chromosome levels. Two cases for which whole genome sequencing data were
available were excluded from the analysis, due to complicating factors. Sample TCGA-
24-2852 was predicted by ASCAT [134] to harbor tetraploid7 genomes in both tumors,
whereas a difference in ploidy between primary and relapse tumor was predicted for
TCGA-61-1916.
As whole genome sequencing data was available on five of seventeen triplets8, but Ag-
ilent 1M array based copy number levels were generated for all triplets, we compared
the results of clonal structure reconstruction of array based clonal subsets to whole
genome sequencing based tumor clones. A similar pattern of primary and relapse sub-
clones were observed, with the primary subclone 3 and 4 identified using whole genome
sequencing data, being grouped into a single clone 3 when evaluating array based copy
numbers (Figure 2.3.2 B, Figure 2.3.3). We thus concluded that the DNA copy number
profiles obtained using arrays are able to provide reliable subclone reconstruction, but
with lower granularity than whole genome sequencing.
2.3.2.2 CLONAL EVOLUTION PATTERNS ASSOCIATE WITH CLINICAL RESPONSE
Using the Agilent array data, we generated clonal structures and tumor progression
models for thirteen of seventeen triplets. At least two different subclones, representing
at least 10% of the tumor cell population, were detected in eleven of thirteen primary
tumors. Similarly, we found that eleven of thirteen relapse tumors consisted of at least
two subclones (data not shown). The number of subclonal populations in the primary
tumor was not predictive of the number of clones identified in the relapse sample. In-
terestingly, subclones in all thirteen relapse tumors were found to have evolved from
ancestral cells from which the primary tumor had also been derived.
6Having three copies of the complete genome.
7Having four copies of the complete genome.
8A set of samples consisting of the normal, primary tumor and relapse tumor biopsies.
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Figure 2.3.5: Patient survival after second surgery. Kaplan-Meier curve of survival from the
time of second surgery.
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The number of clonal populations may be indicative of the level of intratumoral het-
erogeneity that is present in a specific tumor sample. We did not observe a difference in
the number of subclones between tumors that relapsed within 24 months after surgery
(n = 5) and tumors that relapsed later than 24 months post surgery (n = 8). How-
ever, we noticed that four out of five tumor pairs displaying an increase in the number
of subclonal populations resulted in a relapse tumor that was subsequently resistant
to platinum therapy9, whereas all eight tumors in which the number of subclones was
similar or less than the number observed in the primary tumors responded to subse-
quent platinum administration (Figure 2.3.4). As a result, the overall survival after
the last surgery between these two groups trended towards statistical significance, de-
spite the small number of patients included in the analysis (p-value = 0.09, n = 13,
Figure 2.3.5).
2.3.2.3 DISCUSSION
We performed our parsimonious subclone structure reconstruction on a set of seventeen
matching primary and relapse ovarian carcinomas and showed that intratumoral het-
erogeneity plays in important roles in this disease. Through an approach of clustering
copy number segments into bins of similar magnitude, we identified multiple subclones
in all primary and relapse samples. Comparative analysis of the number of relative pro-
portion of clonal subpopulations in primary and relapse tumor samples enabled us to
construct hierarchical trees of tumor progression in thirteen of seventeen cases. Inter-
estingly, all relapse tumors that showed an increase in clonal complexity relative to the
primary tumor were found to be resistant to chemotherapy, regardless of the number
of subclonal populations found in the primary tumor.
The implications of this findings for treatment may be multi-fold. In an era with
an increased interest in individualized therapies, our results suggest that the adequate
9Chemotherapy with cisplatin as the anti-neoplastic reagent
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choice of a therapeutic modality should depend on the molecular profiling of each tumor
sample separately, and the relative level of genomic complexity pre- and post-treatment.
Importantly, precision medicine may only be able to be curative when targeting genomic
abnormalities found in all tumor subclones. We showed that as a result of surgical re-
section and cytotoxic chemotherapy, some subclones are lost whereas others remain
and result in tumor relapse. We demonstrated that each tumor follows a unique path
of disease relapse and tumor progression. These observations confirm previous results
obtained in pediatric acute lymphoblastic leukemia and acute myeloid leukemia (AML)
[71, 139]. Our results extend previous studies of pre- and post-treatment ovarian car-
cinomas which showed intra- and inter-patient genomic diversity but that were limited
by small sample sizes and single genomic platforms [140, 141].
2.4 ANALYSIS OF INTRACRANAL GERM CELL TUMOR LOSS OF HETEROZY-
GOSITY DATASET
2.4.1 INTRODUCTION
Intracranal Germ Cell Tumors (IGCT) are a group of rare heterogeneous brain tumors
that are clinically and histologically similar to the more common gonadal GCTs. IGCTs
show great variations in their geographical and gender distribution, histological com-
position and treatment outcomes [142–148]. We have participated in an in-depth anal-
ysis of the genetic abnormalities of IGCTs through the collaboration with the Wheeler’s
group (Baylor College of Medicine, Huston, TX 77030), performed subclonal structure
reconstruction based on genome-wide SNP array probe intensity data. Here we mostly
focus on the aspect of subclone analysis. Please refer to Appendix Section A.2.2 for
methods regarding data acquisition, and Linghua et al. Nature (2014) [149] for a de-
tailed report.
This experiment procedure resulted in two data tracks, B allele frequency (BAF),
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which describes the amount of heterozygosity, and probe intensity log2 R ratio (LRR),
which describes the total amount of DNA, at each probed location. For germline alleles
that are present in all cells, BAF can either be 0, if the two copies of the allele are all
reference, or homozygous reference; 0.5, if one of the two copies of the allele is different
from the reference, or heterozygous; and 1.0, if the two copies of the alleles are all
different from the reference, or homozygous alternate. The fact that BAF segments
that are of other values than these three have been observed suggests that the tumor
samples contain subclones. Through processes such as balanced loss-of-heterozygosity
(LOH), in which a cell lose a segment of its chromosome, and then later repaired by
copying the corresponding region from its homologous chromosome, such region could
appear to be all either homozygous reference or alternate, effectively shifting the BAF
segment away from 0.5 if such events are not present in all cells. We took advantage of
this signal to construct the parsimonious subclonal structure.
Please refer to Table 4.0.1 for a summary of input data types and major conclusions.
2.4.2 METHODS
The fact that Equation 2.11 and Equation 2.12 do not care about data type specific
properties, such as e.ACN , makes the method expandable to other data types as well.
Here we give an expansion to LOH events based on microarray BAF data.
Definition 2.16. BAF is defined as
BAF =
Non-Reference Allele Count
Total Allele Count
Lemma 2.2. For a heterozygous region in a diploid genome, E{BAF}= 0.5; for a homozy-
gous region in a diploid genome, E{BAF}= 0 or E{BAF}= 1.
Proof. In a heterozygous region,
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E{(Non-Reference Allele Count)} = 0.5(Total Allele Count)
=⇒
E{BAF} = 0.5
In a homozygous region,
E{(Non-Reference Allele Count)} = 0
or
E{(Non-Reference Allele Count)} = (Total Allele Count)
=⇒
BAF = 0
or
BAF = 1
Definition 2.17. mirrored B allele frequency (mBAF) is defined as
mBAF =

BAF BAF≥ 0.5
1− BAF BAF< 0.5
(2.14)
Corollary 2.3. For a heterozygous region in a diploid genome, E{mBAF} = 0.5; for a
homozygous region in a diploid genome, E{mBAF}= 1. (Lemma 2.2 and Definition 2.17)
56
Definition 2.18. A segmental somatic LOH event, eLOH, is defined as eLOH = {S} for a
segment on the genome, specified by S, whose heterozygosity has been lost (mBAF = 1).
Definition 2.19. An observed somatic LOH event, oeLOH, is defined as oeLOH = {eLOH, C P}
for a LOH event eLOH observed in C P > εd fraction of the total cells, with some detection
sensitivity εd > 0.
Definition 2.20. An observation, OLOH, is defined as OLOH = {oeLOH1 , oeLOH2 , . . . , oeLOHn } for
a segmented mBAF profile with n segments of mBAF 6= 0.5. Observed somatic LOH events
are identified with genomic segmentation algorithms, which will result in non-overlapping
segments. The CP for any oeLOH, with a segmental mBAF mean (u, output of segmentation
algorithm), can be calculated by the following equation
∵ 1 · C P + 0.5 · (1− C P) = u
∴ C P = 2u− 1 (2.15)
Definition 2.8 and Definition 2.9 remain the same, thus Lemma 2.1 and Corollary 2.1
remain true.
Definition 2.21. An actual (observed) genomic profile, ALOH, is defined as ALOH = {ALOHl }, l =
1,2, . . . for each unique location Ll on the genome. Since at most 1 oe
LOH exists so that
Ll ∈ oeLOH.eLOH.S (Lemma 2.1), ALOHl is calculated as following
ALOHl =

1× oeLOH.C P + 0.5× (1− oeLOH.C P) ∃!oeLOH ∈ OLOH : Ll ∈ oeLOH.eLOH.S
0.5 otherwise
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which can be simplified as
ALOHl =

0.5(1− oeLOH.C P) ∃!oeLOH ∈ OLOH : Ll ∈ oeLOH.eLOH.S
1 otherwise
(2.16)
Definition 2.22. A model genomic profile, M LOH, is defined as M LOH = {M LOHl }, l = 1, 2, . . .
for each unique location Ll on the genome. Since for any given subclone C
j, at most 1 eLOH
exists for C j.G so that Ll ∈ eLOH.S (Corollary 2.1), M LOHl is calculated as following
Ml =
m∑
j=0

1× C j. f ∃!eLOH ∈ C j.G : Ll ∈ eLOH.S
0.5× C j. f otherwise
(2.17)
All other definitions remain the same as the case for CNV events, and theorems,
lemmas, and corollaries can be proven in similar fashions. A subclone profile can thus
be constructed, using the same method as described by Equation 2.11, Equation 2.12,
and Listing 2.1.
First, the whole genomic BAF data of a tumor sample was filtered to exclude those
locations that were identified as “homozygous” in the paired-normal sample to generate
somatic LOH event profile (Figure 2.4.1 A), and from it a mBAF (Figure 2.4.1 B) [150]
profile was calculated by the following rules:
The mBAF profile was then subjected to segmentation with Circular Binary Segmen-
tation algorithm [151] (Figure 2.4.1 C, D), and the CP values are calculated with Equa-
tion 2.15 (Figure 2.4.1 E).
Next, CP values were clustered to further reduce noise by assigning each cluster a
centroid value (Definition 2.15). A subclone profile was then constructed (Figure 2.4.1
F) according to the parsimonious model described in Section 2.2.
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Figure 2.4.1: Clonality analysis of a representative case (N10, an immature teratoma10). A)
The somatic BAF. The BAF data is filtered to only retain those that are heterozygous in its nor-
mal sample. B) The mBAF. The mBAF data is acquired by mapping all BAF data points smaller
than 0.5 to 1 - BAF. C) The segmented mBAF frequency. The mBAF is then subjected to circu-
lar binary segmentation so that continuous segments of LOH can be identified. D) The copy
number probe log 2 ratio track of the microarray is shown to illustrate that there is no ob-
servable copy number alteration that is correlating with the observed LOH pattern, indicating
that the multi-level LOH is a result of multi-clonality. E) The segmented mBAF values are con-
verted to CP. CP represents, for any given LOH event, what is the fraction of cells that are har-
boring the event, out of the entire cell population measured. F) Utilizing the CP, a subclone
profile is constructed according to a linear heritage model, in which more prevalent events are
present in earlier clones, on which less frequent events are accrued.
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2.4.3 RESULTS
The analysis revealed that 71% of all the investigated IGCT genomes are subclonal. It
also verified that SNP array BAF track can be a viable source for subclonal analysis.
More details about this study can be found in Linghua et al. Nature (2014) [149].
2.5 CONCLUSION
In this chapter, I described our initial efforts to attempt the recovery of the underlying
subclonal structure from genomic profiling data. The data clearly indicated that the
cell populations found in a tumor sample are more complex than a simple normal +
tumor segregation. Using the signals, we were able to reconstruct linear parsimonious
subclonal structures from CNV measurements in the form of RDR, as well as LOH events
derived from BAF. We showed examples that NGS, as well as array assay, can all be
viable sources for identifying clonality, although NGS has been shown to provide higher
resolution. This work was to our knowledge the first attempt to tackle this issue, and our
method was presented at TCGA 1st Annual Scientific Symposium as an oral presentation
(Nov, 2011).
However, an important aspect of the described method, which should not be dis-
missed easily, is that the linear parsimonious subclonal structure, although motivated
by a sound biological modal that the more mutated a genome is, the more unstable it
would become and the easier to produce more mutations, may not be the only possible
structure that is able to explain the observation. This is largely due to the fact the the
widely used whole genome profiling techniques, such as array or NGS, require tissue
homogenization and DNA fragmentation as part of the sample preparation process, ef-
fectively losing the linkage information as in whether two events were originally from
the same cell. In the case that the CP of two events are all greater than 50%, the linear
heritage model IS in fact the only possibility, as, due to pigeon hole principle, they can-
60
not separately exist on different cell populations whose fractions sum up to be greater
than 100%. But for low frequency events, this ambiguity would be present. Consider
two events A and B, with CP values of 20% and 40% respectively, the linear parsimo-
nious method would result in a structure that subclone 1 containing only B derived
form the normal cells, taking up 20% of the entire population; and subclone 2 derived
from subclone 1, inheriting the event B, but in addition also contains event A, taking
up 20% of the entire population. An alternative structure would be that, irregardless
of biological feasibility, subclone 1 and subclone 2 are independently derived from the
normal tissue, containing event B and A respectively, and each takes up 40% and 20%
of the entire population respectively. Mathematically, these two structures will result in
exactly the same observation, yet they represent fundamentally different tumorigene-
sis mechanisms (E.g. in model 1, B could be the driver event; In model 2, the patient
might be genetically pre-exposed to cancer, and A and B are separate, second hits to an
already weakened tumor suppressing pathway). In the next chapter, I will describe an
improved method that enumerate all possible structures, instead of just the linear one.
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3
Exhaustive Enumeration
I
N THE PREVIOUS CHAPTER, I described a method that is able to reconstruct
the linear parsimonious subclone structure based on somatic Copy Num-
ber Variation (CNV) or loss-of-heterozygosity (LOH) data. Yet the diffi-
culty still remains that the Cell Prevalence (CP) of individual events measured in a
large population of tumor cells, as is the case in “bulk” tumor sequencing or microarray
genotyping experiments, do not retain the underlying linkage information that exists
between individual somatic events i.e. whether or not two or more mutation events
are present within the same cell. Unfortunately, given n mutation events, there are in
total n! possible subclone structures, and often a large number of these can account
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for the CP measurements equally well. This makes it very difficult or impossible to un-
ambiguously reconstruct subclonal evolution from per-locus CP observations. Recently,
computational methods have been developed to reconstruct clonal structures that ei-
ther exploit specific biological assumptions [152] to choose between mathematically
equivalent structures (most importantly, the assumption of “Shallowness”, which dic-
tates that the depth of the evolutionary tree is minimal, would be in favor of branching
structures); or by using Markov Chain Monte Carlo (MCMC) sampling based Bayesian
inference [153] to explore the solution space of highly possible phylogenies with a
Dirichlet process prior. Both of these methods require high-precision allele frequency
(AF) measurements of one specific variant type: Single Nucleotide Variation (SNV).
For a comparison of performance, please refer to Appendix Section A.1. Even more re-
cently, several new method have published that either estimate model parameters with
Expectation Maximization (EM) while take advantage of physically separated samples
[154]; or provide the ability to integrate multiple data types (e.g. CNV, LOH, SNV), and
jointly estimate the subclone profile. Both of these methods do not explicitly maintain
the constraint that the subclones fit within a consistent phylogeny [155]; or model the
potentially multi-furcating tumor phylogeny with a bifurcating tree, without the abil-
ity to consider multiple tumors from a single patient (such as primary / relapse pairs)
[156].
3.1 INTRODUCTION
Based on our experience working with two similar yet distinct data types: CNV and
LOH, we came to realize that the fundamental signal for subclone structure reconstruc-
tion is not tied to any specific data type, but the CP value that describes the fraction of
cells harboring a somatic event. Here we discuss a more general approach that is able
to accept many types of somatic variation data (e.g. SNVs, CNVs from either microar-
ray or Next Generation Sequencing (NGS), LOH, etc.) as input. Moreover, the method
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enumerates all possible subclone structures that are consistent with the bulk CP mea-
surements from the input. It is capable of reducing this solution space significantly, often
to a single, unique solution when data from multiple tumor biopsies, such as primary
and relapse from the same patients, are available. In the event that more than a single
alternative subclone structure still remains after such trimming, it is often possible to
derive high-confidence linkage information between subsets of loci based on the con-
sensus of all remaining structures. In such cases, we focus not on efforts to disambiguate
mathematically equivalent solutions, but rather on using the complete set after pruning
procedure in a statistical framework to determine e.g. the probability that two given
mutations are present within the same subclone (mutation co-localization), or that
whether one mutation pre-dates another (mutation ordering). Such co-localization
information may reveal e.g. that two distinct mutations that each sensitizes the cancer
cells to specific drugs are, in fact, present in a single subclone. Given the high incidence
and therapeutic challenges posed by chemoresistant tumors, knowledge of mutation
co-localization may allow for more accurate and potentially more efficacious targeted
therapeutics aimed at countering or preventing chemoresistance. Moreover, if such a
novel mutation in a chemoresistant tumor is present in every cell of the relapse sample,
it may be a top candidate in the search for driver mutation in chemoresistance (variant
prioritizing).
3.2 METHODS
A full implementation of the described method is freely available under the MIT li-
cense at https://github.com/yiq/SubcloneSeeker. At the time this dissertation
is written, the code repository is at commit e01e9b.
An overview of the entire workflow of subclone structure reconstruction using Sub-
cloneSeeker is as the following:
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1. Depending on the type of input data, mutation events and their associated allele
frequencies are called by detection methods (Chapter 1, Section 1.3)
2. The allele frequencies of events are converted into CP values, and then subjected
to clustering. If more than one sample is available, the clustering will be done
in a multidimensional space, in which the number of dimensions is equal to the
number of samples.
3. The resulting somatic event clusters (clustered by CP) serve as the input to the
exhaustive enumeration based subclone structure reconstruction algorithm “Sub-
cloneSeeker”. This will result in a set of solutions that are biologically plausible,
and mathematically consistent with the input.
4. Further trimming can be performed on the solution set, such as trying to merge
multiple samples into a unified evolution tree.
5. Mutation (cluster) co-localization can be inferred from the trimmed solution set.
3.2.1 A UNIFIED FRAMEWORK FOR SUBCLONE STRUCTURE RECONSTRUCTION THAT IN-
CORPORATES ALL TYPES OF GENOMIC VARIANTS
We define a subclone as a collection of cells in the tumor sample that harbor the same set
of genomic variants, including SNVs, Structural Variations (SVs), CNVs, LOHs, etc. The
only requirement for a data type to be included in the analysis is the ability to derive
the fraction of the cells within the tumor sample in which the mutation is present, a
quantity that has also been referred to as “cell prevalence” or CP [157]. In a simplified
example, a heterozygous SNV in a copy number neutral region with an AF of 30%
would correspond to a CP of 60% (Figure 3.2.1 A). It is worth mentioning that the
estimation of CP is no trivial task, and should be given ample consideration. Situations
such as SNVs in CNV regions will need correction techniques. The same CNV region,
interpreted with different absolute copy number (ACN) states, would also results in
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ambiguity. A number of tools have been developed to facilitate CP estimation, including
ASCAT [134] and ABSOLUTE [135], which estimates the absolute copy number states of
CNV regions, and PyClone [157], which jointly estimates the CP of SNVs. Our method
requires as input CP measurements, regardless whether these measurements represent
SNVs, CNVs, or some other type of genetic variation, allowing it to consider each such
variant type, or any combination of them from a given sample. We note that, as a
preprocessing step, our method clusters together variants with the same (or similar) CP
values to minimize measurement uncertainties, and assumes a priori that clusters are
the smallest independently inherited unit (i.e. all variants in each such cluster are co-
localized in the same genomes). The input to our downstream methods is an ordered
list of CP values, corresponding to those clusters.
3.2.2 DATA PREPARATION OF VARIOUS GENOMIC VARIATION TYPES
Various types of raw data are processed, in data-type specific ways, into somatic events.
Whole genome copy number measurements This is done either by whole genome
sequencing (WGS) or Array comparative genome hybridization (aCGH) measure-
ment on paired tumor-normal samples from a cancer patient. In the case of
WGS, read depth (RD) is measured within large genomic window (e.g. 10kb). For
aCGH, hybridization probe intensities are measured, and often averaged across
multiple probes. Relative copy number (RCN) measurement is obtained by nor-
malizing tumor read depth or hybridization intensity first to the total amount of
DNA per sample (e.g. the total number of reads), followed by normalization to the
corresponding measurements in the normal sample. These normalization steps
eliminate germline events shared by both the tumor and the normal genomes,
and keep only the somatic events
Whole genome LOH measurement The procedure to work with LOH measurement
has been described in Chapter 2, Section 2.4.2.
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Segmentation The RCN derived from CNV or mirrored B allele frequency (mBAF) mea-
surements in LOH dataset is then subjected to segmentation algorithms, such as
DNAcopy [138, 151] or HMMSeg [158], to identify continuous regions with the
same underlying copy number or LOH state, and to delineate event boundaries
of the corresponding events.
SNV AF estimation Ultra deep sequencing SNV data does not need to be segmented,
however their AF needs to be accurately estimated, e.g. using PyClone [157],
which also performs CP estimation
3.2.2.1 CELL PREVALENCE CALCULATION
CP is defined as in what percent of all the cells being examined does one specific event
exist. Different data types require different techniques to perform this calculation.
Whole Genome CNV events: For whole genome CNV events derived from either WGS
RD or aCGH probe intensity data, it is important to have a good estimation, or better
yet, direct measurement, on the ploidy1 (p). Various software packages already exist
to estimate p, such as ASCAT [134], CNAnorm [159] and ABSOLUTE [135]. Moreover,
an ACN needs to be called for every CNV event from RCN that is usually in the form of
log2(Tumor/Normal ratio). In the examples shown in this chapter, the ACNs are called
with the same Maximum Likelihood Estimation detailed in Chapter 2, Section 2.4.2. In
the case of WGS, log 2 ratio of read depths are obtained as described in Section 3.2.2.
For microarray, since the probe intensity (PI) is often already in log 2 ratio form to some
common reference sample, the tumor to normal ratio is calculated with subtraction in-
stead of division.
Assuming that at any genomic location where a CNV event is identified, a cell either
does or does not have the event, with ACN estimated, the CP can then be calculated as
1The number of copies of a complete genome in a cell. Normal cells have two copies, thus diploid.
Tumor cells with copy number variation could potentially contain three copies, or triploid, or more.
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∵ ACN · C P + 2 · (1− C P) = RCN
∴ C P = RCN− 2
ACN− 2 (3.1)
Whole genome LOH events: Please refer to Chapter 2. Section 2.4.2
SNVs: With accurate allele frequency estimation made available by ultra-deep se-
quencing and software advancements [157], CP can also be derived from SNVs along
with allele specific copy number quantifications. For example, in diploid2 regions,
C P = 2 · AF for heterozygous SNVs, and C P = AF for homozygous SNVs.
3.2.2.2 CLUSTERING
Because the measurement of CP is potentially noisy, we attempt to mitigate its effect
through clustering on CP to identify distribution modes. Examples shown in this chapter
are clustered with the kernel density function in R, with its bandwidth calculated by
the Pilot Estimation of Derivatives [160]. Users can choose to substitute with more
advanced techniques, such as MCLUST [161]. When multiple samples are available, it
is important to perform clustering on multi-dimensional space, in which the dimensions
equal the number of samples, to identify independently inherited clusters.
3.2.3 SUBCLONE STRUCTURE RECONSTRUCTION
Given n somatic events (or clusters, referred to as clusters henceforth; see Definition 3.3
and Definition 3.7), each with an associated, distinct CP value, we enumerate all pos-
sible “evolution trees” where mutation events occurring along the tree branches give
raise to new subclones in a successive fashion (Figure 3.2.1 B). For n clusters, this pro-
cedure results in n! distinct subclone structures (Theorem 3.5) assuming that 1) cells
2Having two copies of the complete genome.
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in a tumor mass are derived from normal tissue cells or existing tumor cells through
mitosis, in which recombination is unlikely to occur; and 2) the same mutation event
does not spontaneously occur in two different subclones, nor does a mutation get lost
from a subclone. Each subclone structure contains exactly n distinct subclones with
associated subclone frequency (SF), plus a “null” subclone without any mutation, rep-
resenting the normal tissue component within the tumor sample (and its SF the “normal
tissue contamination”). SF is assigned to each subclone so that all subclones within a
given structure, when put together, give rise to the same cluster CP list as the input.
In order to satisfy this condition, our procedure may need to assign negative SF values
to one or more subclones; such subclone structures are not biologically plausible, and
are removed from further consideration. As demonstrated later (Figure 3.3.2), only a
small fraction of the structures are biologically plausible (we term these “viable sub-
clone structures”).
3.2.3.1 FORMAL DEFINITION OF SUBCLONE RECONSTRUCTION PROBLEM
Definition 3.1. A chromosomal location, L, is defined as L = {chromosome, position},
which describes a location on the genome.
Definition 3.2. A chromosomal segment, S, is defined as S = {L, length}, which describes
a continuous region on the genome.
Definition 3.3. A somatic event (henceforth referred to as “event” if without specification),
e, is a general symbol representing any genomic variation presented in the tumor sample,
that is not found in the paired normal sample. e can be one of the following:
• A segmental somatic CNV event, eCNV, which is defined as eCNV = {S, ACN} for a
segment on the genome specified by S, with the absolute copy number state of ACN.
• A segmental somatic LOH event, eLOH, which is defined as eLOH = {S} for a segment
on the genome, specified by S, whose heterozygosity has been lost (mBAF = 1).
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• A somatic SNV event, eSNV, which is defined as eSNV = {L, GT} at a position on the
genome, specified by L, with a genotype, specified by GT, either being “heterozygous”
or “homozygous alternate” in the case of diploid genome, or other more complex
genotypes in the case of aneuploid3 genome.
Definition 3.4. An observed somatic event (henceforth referred to as “observed event” if
without specification), oe, is defined as oe = {e, C P} for an event e observed in C P > εd
fraction of the total cells, with some detection sensitivity εd > 0.
Definition 3.5. An observation, O, is defined as O = {oe1, oe2, . . . , oen} for a tumor
genome with n detected events. The detection process if data-type specific. In any case,
oe.C P should be, or can be derived, from the output of the detection process (Section 3.2.2.1).
Definition 3.6. The complete events set, E, is defined as E = {oe.e|oe ∈ O}.
Definition 3.7. A set of event clusters, P, is defined as a partition over an observation O,
that, for a given error margin εP ≥ 0, satisfies
∀p ∈ P :(∀oe ∈ p, oe′ ∈ p : |oe.C P − oe′.C P| ≤ εP)
and
∀p ∈ P, p′ ∈ P, p 6= p′ :(∀oe ∈ p, oe′ ∈ p′ : |oe.C P − oe′.C P|> εP)
Each element p ∈ P is called an event cluster. We denote p.C P =
∑
oe∈p
oe.C P
|p| as the
cluster centroid.
We further impose, without loss of generality that, P is a sorted set, with respect to the
cluster centroids, in descending order.
3Having a ploidy that is other than 2
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∀i ∈ [1, n′], j ∈ [1, n′], i < j : pi.C P > p j.C P
Definition 3.8. A subclone profile, C, is defined as C j = {B, f } j, j = 0..m, in which
C j.B = {b1, b2, . . . , bn′} j is a row vector whose value b ji indicates whether the j-th subclone
contains the somatic events belonging to the event cluster pi. The 0-th subclone is a special
one representing the normal tissue component, thus C0.B = {0, 0, . . . , 0}. ∀ j ≤ m, j′ ≤
m, j 6= j′ : C j.B 6= C j′ .B. C j. f represents the fraction the j-th subclone occupies over the
entire cell population, or SF, and that
∑m
j=0 C
j. f = 1.
Definition 3.9. For any given subclone profile C, it is said that
• C is biologically plausible, if ∀ j ≤ m : C j. f ≥ 0.
• C is not biologically plausible, if ∃ j ≤ m : C j. f < 0.
Definition 3.10. A subclone profile C with m+1 subclones is a solution to an observation
O with a clustering partition P having n′ clusters when the following is satisfied
[C1. f , C2. f , . . . , Cm. f ]×

b11, b
1
2, · · · b1n′
b21, b
2
2, · · · b2n′
...
... . . .
...
bm1 , b
m
2 , · · · bmn′
= [p1.C P, p2.C P, . . . , pn′ .C P]
Definition 3.11. A subclone structure, SS, over a given subclone profile C, is defined as a
multi-furcating tree whose nodes are individual subclones in C. It is apparent that all SS
over a given C with m + 1 subclones have exactly m + 1 nodes. If C j ∈ SS is the parent
node to another node C j
′ ∈ SS, such relationship is denoted as C j ⇒ C j′ or C j′ ⇐ C j; If C j
is an ancestral (not necessarily direct parent) node to another node C j
′
, such relationship
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is denoted as C j → C j′ or C j′ ← C j. If neither C j nor C j′ is an ancestral node to the other,
such relationship is said as “C j and C j
′
are parallel”, and denoted as C j‖C j′ .
Due to the unique biology of tumorigenesis, we make the following assumptions
• Cells in a tumor mass are derived from germline cells or parental, existing tumor
cells through mitosis, in which recombination is unlikely to occur.
• The same event (with respect to a boundary resolution) would not spontaneously
occur in two subclones without a descendant relationship, nor would pre-existing
events revert back to the normal state in a descendant subclone
Definition 3.12. A subclone structure SS over a given subclone profile C is said to be
evolutionary, if the following conditions are satisfied
• ∀C j, C j′ , C j → C j′ : ∀b ji = 1 : b j
′
i = 1
• ∀C j, C j′ , C j ⇒ C j′ : ∀b ji = 0, b j
′
i = 1 : ∀C j′′‖C j′ : b j
′′
i = 0
• ∀C j, C j′ , C j ⇒ C j′ : ∀b ji = 0, b j
′
i = 1 : ∀C j′′ → C j : b j
′′
i = 0
We term ∃C j, C j′ , C j ⇒ C j′ : ∃b ji = 0, b j
′
i = 1 as “Event cluster pi first appeared in
subclone C j
′
”
We term ∃C j, C j′ , C j → C j′ : ∃b ji = 0, b j
′
i = 1 as “Event cluster pi appeared after subclone
C j”
Theorem 3.1. For any given C over which evolutionary subclone structures exist, only one
evolutionary subclone structure exists.
Proof. Assume that there are two subclone structures, SS1 and SS2, over the same sub-
clone profile C , that are both evolutionary. Due to Definition 3.12
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∃C p1, C p2, C j :

C p1⇒ C j in SS1 =⇒

∀bp1i = 1 : b ji = 1
∀b ji = 0 : bp1i = 0
C p2⇒ C j in SS2 =⇒

∀bp2i = 1 : b ji = 1
∀b ji = 0 : bp2i = 0
C p1.B 6= C p2.B 6= C j.B
Lemma 3.1. ∀bp1i = 0, b ji = 1 : bp2i = 0
Proof. Assume that
∃bp1i = 0, b ji = 1 : bp2i = 1
Due to Definition 3.12, the only possible relationship between C j and C p2 in SS1 is
that C j → C p2 =⇒ ∃bp2i = 1 : b ji = 0. However, this contradicts with the condition
that C p2⇒ C j in SS2 =⇒ ∀bp2i = 1 : b ji = 1.
Lemma 3.2. ∀bp2i = 0, b ji = 1 : bp1i = 0
Proof is similar to Lemma 3.1
Combine Equation 3.1, Lemma 3.1, and Lemma 3.2, we have
∀b ji = 0 : bp1i = 0, bp2i = 0
∀b ji = 1 : (bp1i = 0, bp2i = 0)∨ (bp1i = 1, bp2i = 1)
Thus we have
∀i : bp1i = bp2i
This contradicts with the condition that C p1.B 6= C p2.B
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Definition 3.13. The problem of subclone structure reconstruction, is that given an obser-
vation O, along with a clustering partition P with n′ event clusters, find all evolutionary
subclone structures SS whose corresponding, biologically plausible, subclone profiles C are
solutions to O with clustering partition P.
Theorem 3.2. For a given evolutionary subclone structure SS whose corresponding sub-
clone profile C is biologically plausible and a solution to a given observation O with a
clustering partition P having n′ clusters, let C pi denote the subclone in which pi first ap-
peared, the following condition is true
∀pi ∈ P : pi.C P = C pi . f +
C pi→C j∑
C j
C j. f
Proof. Because pi first appeared in C
pi , from Definition 3.12 we have
bpii = 1
∀C j ← C pi : b ji = 1
∀C j′ → C pi ∨ C j′‖C pi : b j′i = 0
Because C is a solution to O with clustering partition P, from Definition 3.10, we
have
pi.C P =
∑
C j
C j. f × b ji
=
C j→C pi∨C j‖C pi∑
C j
C j. f × b ji + C pi . f × bpii +
C j←C pi∑
C j
C j. f × b ji
= C pi . f +
C pi→C j∑
C j
C j. f
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We define cC j as
cC j = C j. f + C j→C j′∑
C j′
C j
′
. f
which represent the sum of the subclone frequencies of all nodes in the subtree with C j
being the root.
Corollary 3.1. For a given evolutionary subclone structure SS whose corresponding sub-
clone profile C is biologically plausible and a solution to a given observation O with a
clustering partition P having n′ clusters, if pi ∈ P first appeared in subclone C pi , pi′ ∈ P
first appeared in subclone C pi′ , C pi → C pi′ , then we have pi.C P ≥ pi′ .C P
Proof. From Theorem 3.2, we have
pi.C P =ÓC pi
= C pi . f +
C pi→C j∑
C j
C j. f
pi′ .C P =dC pi′
= C pi′ . f +
C pi′→C j∑
C j
C j. f
Because ∀C j ← C pi′ : C j ← C pi
pi.C P − pi′ .C P ≥ C pi . f
pi.C P ≥ pi′ .C P
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Corollary 3.2. For a given evolutionary subclone structure SS whose corresponding sub-
clone profile C is biologically plausible and a solution to a given observation O with a
clustering partition P having n′ clusters, ∀pi ∈ P, pi′ ∈ P, pi.C P < pi′ .C P, The subclone C j
that contains pi but not pi′ cannot be an ancestral node to a subclone that contains pi′
Proof. C j → C j′ implies that pi first appeared either in C j or some subclone C k →
C j, and pi′ first appeared in C
j′ , according to Corollary 3.1, pi.C P ≥ pi′ .C P, which
contradicts with the condition that pi.C P < pi′ .C P
Theorem 3.3. For a given evolutionary subclone structure SS whose corresponding sub-
clone profile C, having m+ 1 subclones, is biologically plausible and a solution to a given
observation O with clustering partition P, having n′ clusters, it is true that m≥ n′.
Proof. Assume that m< n′. Due to pigeonhole principle,
∃C j : ∃pi ∈ P, pi′ ∈ P : pi and pi′ both first appeared in C j
Thus
pi.C F = pi′ .C F =cC j
This contradicts with Definition 3.7
Theorem 3.4. For a given evolutionary subclone structure SS whose corresponding sub-
clone profile C, having m+ 1 subclones, is biologically plausible and a solution to a given
observation O with clustering partition P, having n′ clusters, it is true that m≤ n′.
Proof. Assume that m> n′. Due to pigeonhole principle,
∃C j 6= C0 : ∀pi ∈ P : pi first appeared in a subclone C j′ 6= C j
Thus, ∃C k⇒ C j : C k.B = C j.B, which contradicts Definition 3.8
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Corollary 3.3. For a given evolutionary subclone structure SS whose corresponding sub-
clone profile C, having m+ 1 subclones, is biologically plausible and a solution to a given
observation O with clustering partition P having n′ clusters, from Theorem 3.3 and Theo-
rem 3.4, we have m = n′.
Corollary 3.3 states that, for a given evolutionary subclone structure SS whose sub-
clone profile C is biologically plausible and a solution to a given observation O with
clustering partition P having n′ clusters, there are exactly n′ + 1 subclones in C .
Theorem 3.5. For a given observation O with clustering partition P having n′ clusters,
there are at most n′! different subclone structures that are evolutionary and their corre-
sponding subclone profiles are biologically plausible and solutions to O.
Proof. First, we denote an evolutionary subclone structure SS with m nodes SSm.
Base case: when |P|= 1, there is only one SS1, C0⇒ C1, that p1 first appeared in C1.
Induction: assume that when |P|= k, the total number of SSk is k!. We introduce pk+1
into |P|, and assume without loss of generality that ∀pi ∈ P : pi.C P > pk+1.C P. SSk+1
can be derived by attaching a new node C k+1, in which pk+1 first appeared, onto existing
SSk. From Theorem 3.2, in any given SSk+1, C
k+1 cannot be the parent of any subclones
in SSk, leaving the only possible placement for C
k+1 to be a child of the existing k + 1
subclones in SSk. Therefore, the number of possible SSk+1 is k!× (k+1) = (k+1)!
3.2.3.2 EXHAUSTIVE ENUMERATION METHOD
An exhaustive enumeration algorithm is designed to derive all possible structures in
the similar fashion as described in the induction step of the proof to Theorem 3.5, and
outlined as Listing 3.1.
The function “treeEnum(T, P)” enumerate all SSk+1 from all SSk, exactly as described
in the proof of Theorem 3.5, through a recursive call to itself when P is not exhausted,
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Initialize a tree T with a root that contains no event
treeEnum(T, P);
function treeEnum(T, P):
p = first_elem(P) ; the event cluster with highest CP
for n in all existing nodes of T:
create a new node n’
n’. first_event = p
add n’ to T as a child of n
if P.size == 1:
Evaluate(T)
else:
treeEnum(T, P-{p})
end -if
remove n’ from T
end -for
end -function
function Evaluate(T):
for n in post -order -traverse(T):
if n is leaf:
n.SF = n.first_event.CP
else:
n.SF = n.first_event.CP - sum(n.children.SF)
end -if
if(n.SF < 0) abort
end -for
output T
end -function
Listing 3.1: Pseudo code of the exhaustive enumeration algorithm.
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and evaluate whether the subclone profile, to which the resulting structure T corre-
sponds, is biologically plausible and a solution to the observation O with clustering
partition P.
The function “Evaluate(T)” will, through a post-order tree traverse, try to assign a
SF ( f as mentioned in Definition 3.8) value to each of the tree nodes so that at the end
the subclone structure is a solution to the observation(O, P). If the function visits a leaf
node, it will assign the CP of the event clusters first appeared in the node; If the function
visits an internal node, it will assign the CP of the event clusters first appeared in the
node, minus the sum of the SF of all its descendant nodes (because they all inherit those
events). It it can do so without assigning any node a less-than-zero SF, the subclone
profile C the specific tree structure corresponds to is biologically plausible, and the tree
structure is recorded as a feasible solution.
This method will result in a tree-set, which contains all the possible subclone struc-
tures whose subclone profile is a solution to the observation, and the phylogeny between
the subclones. One can choose to further trim the set by external or internal linkage
information, or perform coexistence prediction. An example of all the resulting struc-
tures, along with the assigned CP values, when three event clusters are considered is
given in Figure 3.2.1B.
3.2.3.3 TRIMMING THE SPACE OF VIABLE SUBCLONE STRUCTURES.
Often there are more than one viable subclone structures in the resulting solution set,
corresponding to multiple alternative subclone evolutions. However, if additional “link-
age” data is available, further trimming is usually possible. Such linkage informa-
tion may be either directly observed, such as in the case of spectral karyotype images
[46, 162, 163], single cell colony assays, or single cell sequencing; or indirectly inferred
from e.g. primary and relapse tumor from the same patient. Because typically, the re-
lapse tumor is derived from the primary tumor, they share mutations originating from
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common ancestor subclones, and through such shared evolutionary history the primary
and relapse subclones can be merged into one unified subclone structure, while satis-
fying the following two conditions:
1. After merging, for any given non-leaf node, its children node must have all the
mutations presented in the node itself (extra relapse specific mutations are al-
lowed).
2. No two branches shall have the same mutation simultaneously without sharing a
common parent node who has that mutation.
These two conditions assure the fundamental assumptions concerning tumorigenesis
aforementioned are met. Through this process, if a specific primary (or relapse) tree
cannot be merged with any relapse (or primary) tree, that specific tree is then an invalid
solution, and can be discarded. Figure 3.2.1 C shows examples of two compatible pri-
mary / relapse structures (left) as well as two incompatible ones (right). In the latter
example, the relapse subclone R2 contains two mutations that are found in different
branches on the primary tree (P1 and P3), violating the assumptions above. Any struc-
ture in the primary that has no compatible structure in the relapse, or vice versa, is
discarded from consideration, reducing the solution space.
Figure 3.2.1 (following page): SubcloneSeeker Method Overview. A) Data Preparation: Ge-
nomic variation data (SNVs, CNVs, etc.) is converted into the corresponding CP values, and
clustered into distinct groups. B) Structure Enumeration: Based on the identified CP clusters,
all possible subclone structures, represented as branching tree structures where one subclone
is derived from its “predecessor” by the addition of a mutation (or cluster of mutations), are
visited. During the visit, each subclone on the tree structure is assigned a SF value so that the
implied total CP values for mutations are in agreement with the input CP values. Those struc-
tures with negative SF values are removed from the solution set. C) Solution Trimming: The
aim of this procedure is to merge the subclone structures from the relapse tumor (orange cir-
cles) those from the primary tumor (blue circles) from the same patient. Left Panel: Example
showing a compatible pair of relapse/primary structures. Right Panel: Example showing a
pair of incompatible relapse/primary subclone structures. A subclone in the relapse, R2, can-
not be positioned anywhere within the primary subclone structure because it contains muta-
tions found in separate primary subclones (P1 and P3.), and therefore cannot be derived from
either one or the other.
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3.2.4 MUTATION CO-LOCALIZATION PREDICTION
Useful knowledge can be derived even in cases where there are multiple alternative
subclone structures. Although one cannot determine the precise subclone evolution
with certainty in such cases, the collection of all possible solutions can be used to predict
whether or not two mutations are present in the same cell, i.e. whether or not they are
co-localized within the same subclone. This prediction is based on the fraction of all
viable subclone structures in which two mutations (or more generally, a given set of
mutations) are present in at least one subclone. Such information could potentially
be important in e.g. designing personalized chemotherapy treatment plans. Given n
clusters, there are in total C2n (n choose 2) unique, unordered cluster pairs, each of
which is assigned a status of either “co-localized”, “not co-localized”, or “ambiguous”
(Figure 3.2.2). Furthermore, for two events that are localized in the same subclone, the
timing of the mutations can be easily determined: the event with the higher CP value
appeared earlier, and the event with the lower CP value emerged later.
For any given pairs of somatic event clusters, a co-localization frequency matrix (CLF)
can be calculated as
C LF =
# of solutions∑
i=1
PSi · C L (3.2)
in which PSi is the probability that solution i is the correct solution, which in case no
prior knowledge is available, can be estimated as
PSi =
1
# of solutions
(3.3)
C L is a binary variable that describes whether a given pair of event clusters co-localize
in solution i, which can either be 1, if in at least one subclone the event clusters co-
localize, or 0 if in none of the subclones the event clusters co-localize. This framework
allows us to estimate co-localization giving all structures equal probability to be true,
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CLF$
100%$
67%$ 33%$
With$a$cutoﬀ$of$70%,$$$$$$$$$$and$$$$$$$$$$$is$likely$to$be$in$the$same$subclone;$
Cannot$determine$the$coAlocalizaCon$relaConship$in$the$other$two$pairs.$
$
With$a$cutoﬀ$of$50%,$$$$$$$$$$and$$$$$$$$$,$as$well$as$$$$$$$$$$and$$$$$$$$$are$likely$to$
be$in$the$same$subclone,$$$$$$$$$and$$$$$$$$$$are$unlikely$to$be$in$the$same$
subclone.$
NonAUnique$SoluCon$Set$
CoAlocalizaCon$frequency$matrix$
Figure 3.2.2: Predicting mutation co-localization. In cases where there are multiple viable
subclone structures, we count the fraction of all structures within which two mutation events
are co-localized. This fraction is the probability that the two events are present in the same
subclone. One can also make a “co-localization call” by declaring that two events are co-
localized, if this probability is above a pre-defined threshold.
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or weight towards, or against, specific structures. (e.g. one can reasonably argue that
it is generally unlikely for a patient to develop two, separate tumor subclones without
related by a common ancestor which contains the initial driver mutations, thus placing
a lower prior on those structures in which multiple subclones are derived directly from
the normal tissue.)
3.2.5 SUBCLONE STRUCTURE SIMULATION PROCESS
In order to understand the behavior of our subclone reconstruction algorithm, we de-
signed a tumor subclone structure simulator. The simulator initialize in a state that it
only contains one subclone with no somatic event. This “null” subclone logically rep-
resents the normal tissue before tumor expansion, and mathematically represents the
normal tissue contamination usually found in tumor sample. We also assign a “viability”
value of 100 to this null subclone. The viability value represent the ability for a certain
subclone to grow, and will ultimately determine the SF of each subclone. The simulator
will then repeat the following steps exactly m times to simulate one subclone structure
with m+ 1 subclones
1. From the existing subclones, a “parent” subclone is selected randomly by sampling
from a roulette wheel. The proportion of each subclone on the roulette wheel is
determined by the viability value of the subclone.
2. A new subclone is created, with one additional mutation, and attached as a chil-
dren node to the parent subclone. The mutation is only symbolic, so that allele
frequency can be calculated at the end
3. The viability value of the new subclone is determined by randomly sampling from
a uniform distribution with a range of (0.5×ViabilityParent, 2×ViabilityParent), sig-
nifying that a mutation can be beneficial, detrimental, or neutral to the growth
advantage.
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The process is not meant to accurately model the actual tumor micro-evolution, but
to create a large number of subclone structures with varying topology and CP values.
After the structure is created, each subclone is assigned a SF proportional to its viability
value
C j. f =
Viability j∑
Viability
(3.4)
The CP value for each of the introduced mutations is then calculated, which will serve
as the input to the subclone reconstruction algorithm, as
C Pi =
j≤m∑
j=0
C j. f · b ji ; b ji =

1 subclone j contains mutation j
0 otherwise
(3.5)
The output of the simulation procedure will be a subclone structure, along with the
CP value of all the mutations. The CP values will be used as input to the reconstruc-
tion algorithm, and the subclone structure will be used to check if, among the results
produced by reconstructing, the correct structure has been found.
3.3 RESULTS
3.3.1 THE METHOD ALWAYS CAPTURE THE CORRECT STRUCTURE
We generated simulated tumor samples (Section 3.2.5) comprising 3,4, . . . , 8 mutation
events with distinct CP values (from our experience, we usually see less than 6 subclones
in a clinical tumor sample). For each of these “tumor samples”, we produced a random
subclone structure serving as a “true” structure. We repeated this procedure 1,000
times. In every case, SubcloneSeeker was able to reproduce the “true” subclone struc-
ture as one of the solutions in the complete solution set of viable subclone structures.
This “sanity check” was necessary to ensure that our software worked appropriately for
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simulated datasets.
3.3.2 THE NUMBER OF BIOLOGICALLY PLAUSIBLE SUBCLONE STRUCTURES IS LOW
We also found that the number of viable subclone structures is very low compared to
the number of all possible structures. As Figure 3.3.1 illustrates, the expected number
of viable subclone structures is far less than the theoretical upper-limit (n! for n distinct
CP values, Theorem 3.5).
3.3.3 NORMAL CELL COMPONENT ESTIMATION PROCEDURE IS ACCURATE
As described above, our subclone structure reconstruction method provides in each its
resulting structures a null subclone with no mutations. This is the normal cell com-
ponent of the tumor biopsy, and its fraction the normal cell fraction. We investigated
the accuracy with which our method estimates the normal cell fraction in experimental
data. We applied our method to a dataset created by mixing 10%,20%, . . . , 90%,95%
and 100% sequencing reads from a SNUC cell line sample [164], with reads sequenced
from paired normal tissue (Figure 3.3.2). In this dataset, the non-branching, stepwise
mutation accumulation model (red-cross), a parsimonious solution that always exists
(Chapter 2), produced very accurate estimate for normal cell content among all alter-
native structures (R2 = 0.9705395 to the line y = x).
3.3.4 OUR ALGORITHMIC PROCEDURE IMPROVES ON INTERPRETATION IN PREVIOUSLY
PUBLISHED DATA
In a recent study, Ding, et al. [113] investigated clonal evolution in eight acute myeloid
leukemia (AML) patients. To ensure comparability with the published results, we started
with the somatic mutation clusters and AF values provided in the study (Table 3.3.1),
rather than re-computing them ourselves. With two exceptions, SubcloneSeeker pro-
duced the same subclone structures, and with one exception, came to the same conclu-
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Figure 3.3.2: Normal cell content estimated by subclone reconstruction in a controlled mix-
ing experiment. Dataset is generated by mixing sequencing reads from a Sinonasal Undiffer-
enciated Carcinoma (SNUC) cell-line and matched normal tissue. Data points corresponding
to the subclone structure representing linear mutation accumulation are shown with a red
cross.
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sions (Table 3.3.2). Please refer to Table 4.0.1 for a summary of input data types and
major conclusions.
In the case of patient UPN933124, the primary sample contained two low frequency
clusters, which resulted in a total of 6 different viable subclonal structures, including
the one reported in the original study. However, only one of these was compatible with
the sole viable subclone structure in the relapse, and the resulting single primary /
relapse subclone structure was in agreement with the model presented in the original
paper (Figure 3.3.3 A). In the case of patient UPN758168, the relapse sample yielded
two possible structures, both of which were compatible with the primary structure.
However, the tumor expansion model suggested by either of these structures disagrees
with the expansion model described in the original paper as “a minor clone carrying the
vast majority of the primary tumor mutations survived and expanded at relapse”. Our
subclone structures (Figure 3.3.3 B) suggest, in contrast, that both primary subclones
survived in the relapse. The difference between the two relapse models is which primary
subclone expanded with extra mutations.
3.3.5 ANALYSIS OF WHOLE-EXOME SEQUENCING DATA FROM CHEMORESISTANT vs. PRI-
MARY OVARIAN TUMORS DEMONSTRATES THAT OUR METHOD CAN BE USED TO PRI-
ORITIZE SOMATIC MUTATIONS FOR FURTHER FOLLOW-UPS
We are investigating how high-grade serous ovarian cancers become chemoresistant by
applying SubcloneSeeker to whole exome sequencing datasets on normal, primary tu-
mor and chemoresistant relapse tumor tissue samples from the same patient. Please
refer to Table 4.0.1 for a summary of input data types and major conclusions. Fig-
ure 3.3.4 shows our analysis workflow for prioritizing mutations observed in patients
“S15” and “S17”. Somatic mutations were first clustered in the “Primary AF — Relapse
AF” space to identify discrete modal values, corresponding to distinct subclones (Fig-
ure 3.3.4 A, B, D, E). The allele frequencies of these clusters were then converted to CP
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UPN Cluster Primary AF (%) Relapse AF (%)
933124 Cluster1 46.86 42.23
933124 Cluster2 24.89 0.24
933124 Cluster3 17 40.04
933124 Cluster4 2.39 38.53
933124 Cluster5 0.04 39.65
758168 Cluster1 45.5 44.8
758168 Cluster2 41.8 26
758168 Cluster3 0 17
400220 Cluster1 44.6 36.6
400220 Cluster2 0 13.3
426980 Cluster1 45.4 41.3
426980 Cluster2 45.4 11.5
426980 Cluster3 45.4 0
426980 Cluster4 18.2 0
426980 Cluster5 0 30.1
452198 Cluster1 45.4 18
452198 Cluster2 36 0
452198 Cluster3 11 0
452198 Cluster4 0 18
573988 Cluster1 41.7 14.3
573988 Cluster2 0 21.7
869586 Cluster1 45.4 20
869586 Cluster2 23.3 0
869586 Cluster3 16.4 20
869586 Cluster4 0 20
Table 3.3.1: Summary of data published in Ding et al. [113] that were used in the analysis of
the same AML dataset.
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Figure 3.3.3: Our re-analysis of published primary/relapse AML dataset in Ding et al. Pri-
mary, relapse, and merged subclone structures for two patients, reconstructed with Subclone-
Seeker. A) SubcloneSeeker analysis found 6 alternative primary subclone structures for pa-
tient UPN933124. Only one is compatible with the relapse subclone structure, and the pair is
in agreement with the original study. B) Each of the two viable merged primary/relapse sub-
clone structures for patient UPN75816 suggests that the two primary subclones made it to the
relapse tumor, and further expanded.
Patient ID Primary tumor Relapse tumors Compatible Same conclusion
structures structures structure pairs as Ding, et al.
933124 6 1 1 Yes
758168 1 2 2 No
400220 1 1 1 Yes
426980 1 1 1 Yes
452198 1 1 1 Yes
573988 1 1 1 Yes
804168 1 1 1 Yes
869586 2 1 1 Yes
Table 3.3.2: Summary of the re-analysis results of AML patient samples reported in Ding, et
al.
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values, and subjected to subclone structure reconstruction. In the case of “S15”, both
the primary and the relapse sample yielded a unique structure; these are compatible
with each other (Figure 3.3.4 C). The mutations in cluster “C4” are early events in the
primary, present in every cell of the relapse, and likely contain the driver mutation re-
sponsible for initial tumor expansion. On the other hand, in the relapse sample, the
vast majority (93%) of tumor cells contain the mutations that make up cluster “C3”.
This makes it likely that the mutation(s) conferring the tumor phenotype are part of
this cluster.
In the case of sample “S17”, the primary sample yielded two viable subclone struc-
tures, both compatible with the sole structure in the relapse (Figure 3.3.4 F). Similarly
to sample “S15”, cluster “C4” is likely to contain the initial driver mutation(s), and
cluster “C3”, which is present in all relapse subclones, is likely to contain the mutation
leading to chemoresistance. In both samples, the use of subclone analysis resulted in
information that one can use for variant prioritization, in order to narrow down the
set of somatic events in the search for the causative mutation, both for initial tumor
expansion, and for chemoresistance.
3.3.6 SIMULATION STUDIES DEMONSTRATES THAT OUR STATISTICAL FRAMEWORK IS ABLE
TO ACCURATELY PREDICT WHETHER TWO SOMATIC MUTATIONS, OR CLUSTERS, ARE
LOCALIZED IN A SUBCLONE TOGETHER
To understand the behavior of our methods predicting co-localization of mutations
within subclones, we simulated tumors with 5, 6, and 7 subclones (in each case, 1000
replicates), performed our subclone reconstruction procedure, and carried out muta-
tion co-localization analysis (Section 3.2.4). We used threshold values of 0.7 and 0.5
to call whether two mutations are co-localized, not co-localized, or that the results are
ambiguous (see Figure 3.3.5 for 6 subclones, and Figure 3.3.6 for the complete set). Im-
portantly, at a call threshold of 0.7, our method calls co-localized and not co-localized
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Figure 3.3.5: Performance of mutation co-localization prediction on simulated data. A) Co-
localization prediction statistics on simulated dataset with 6 subclones in each tumor sam-
ple, and a threshold of 0.7. SI — Combined Sensitivity; PPV — Combined positive predictive
value; B) Co-localization prediction statistics on simulated dataset with 6 subclones in each
tumor sample, and a CLF threshold at 0.5.
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tion performance on simulated data. Values plotted are median over 1000 simulations in each
case.
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pairs with 70% sensitivity and nearly 100% positive predictive value (PPV, the fraction
of correct calls in all the calls made). At a threshold of 0.5, sensitivity goes up to nearly
100%, while PPV drops to 80%.
3.3.7 RE-ANALYSIS OF BULK vs. SINGLE CELL COLONY ASSAY DATA DEMONSTRATES THAT
WE ARE ABLE TO ACCURATELY IDENTIFY MUTATIONS THAT ARE PRESENT IN THE
SAME SUBCLONE
In a recent study by Jan et al. [114], hematopoietic stem cell (HSC) from several AML
patients were sequenced to>20,000 depth to measure somatic mutation allele frequen-
cies at several targeted loci. In addition, colonies grown from single cells separated from
the sample were subjected to allele-specific SNV TaqMan assay4 at the same SNV sites,
resulting in direct observations of subclones within the tissue. We used the bulk AF val-
ues obtained from the sequencing data as input to our subclone reconstruction method,
followed by our mutation co-localization prediction procedure. We then compared our
co-localization predictions to the colony assay results. Please refer to Table 4.0.1 for
a summary of input data types and major conclusions. Among four patient samples
for which colony assay data was available, SU030 and SU008 did not yield conclu-
sive results because the AFs at the tested sites were so low (well below 1%) that they
were indistinguishable from measurement noise (Table 3.3.3). SU070 yielded a unique
subclone structure that is in agreement with the structure identified by colony assay
(Figure 3.3.8). SU048 (Figure 3.3.7) produced a result set of 48 viable subclone struc-
tures. Every structure supports that TET2-E1375STOP is the earliest event, followed by
SMC1A and ACSM1 (Figure 3.3.7 A, Table 3.3.4). With a co-localization calling thresh-
old of 0.5, TET2-D1384V, OLFM2 and ZMYM3 co-localize with TET2-E1375STOP and
SMC1A, which is in agreement with the conclusion in the original analysis by Jan et al.
that AML precursor HSC cells contain double mutations (presumably forming a com-
4A quantitative PCR technique, using the TaqMan probe, for genotyping.
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Figure 3.3.7: Analysis results on patient SU048 HSC sample in Jan et al. A) Our model of
subclone evolution constructed based on co-localization probabilities. Left: Consensus struc-
ture supported by all subclone structures. Right: Consensus structure supported by at least
50% of subclone structures. B) Model of subclone evolution reported in Jan et al. constructed
based on colony assay results.
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Figure 3.3.8: Reported and Analysis results on patient SU070 HSC sample in Jan et al. A)
Colony assay results reported in Jan et al. B) Evolution Model reported in Jan et al. based on
the colony assay results. C) The unique evolution tree constructed from the deep sequencing
results on heterogeneous HSC sample
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pound heterozygote) in the TET2 gene. According to our analysis, TET2-E1375STOP
and SMC1A are the two early events, and the two TET2 mutations are already present
in the same, early subclone. This is biologically sensible given that TET2 is involved
in DNA demethylation [165] and SMC1A in chromosome structure maintenance [166].
In addition, the depletion of TET2 in mouse model leads to HSC expansion [167, 168],
and the lack of SMC1A protein predicts poor survival in AML [169]. On the other hand,
the relatively low co-localization probabilities among ACSM1, TET2-D1384V, OLFM2
and ZMYM3 suggest a branching structure for these mutations (Figure 3.3.7 A), rather
than linear mutation accumulation consistent with the colony assay for this patient (the
colony assay found one cell in which all these mutations are present). This points out
the relatively weak power of our method to resolve co-localization among mutations
with very low allele frequencies, as such low frequency mutations can be placed with
relative freedom on multiple branches of the evolutionary tree.
3.4 DISCUSSION
In this chapter I present a novel algorithm to elucidate tumor subclonal structure using
as input CP values of individual, unlinked somatic mutations. This method is able to
analyze many different types of genomic variant data, as long as AF measurements
can be converted into CP values. Because bulk mutation frequency measurements from
fragmentary sequence data or per-site microarray measurements do not retain “linkage”
across such somatic variant sites, often there are many alternative subclone structures
that can account for the input measurements. This method exhaustively enumerates all
such viable subclone structures, tackling the short-comings of the parsimonious method
described in Chapter 2. We were able to show that the number of solutions is usually
much smaller than the theoretical upper limit. Often tumor tissues from multiple phases
of tumor development (e.g. primary and relapse biopsies) are available. In such cases,
the number of subclone structures that are not only consistent with the respective input
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Patient Mutation Variant Allele Reference Allele Variant AF
Read count Read count
SU008 SKP2 45937 624754 0.068492048
SU008 ELP2 1915 504335 0.003782716
SU008 PDZD3 161 100433 0.001600493
SU008 CNDP1 2238 475621 0.00468339
SU030 KCTD4 116061 2090267 0.052603693
SU030 SLC12A1 7754 1163598 0.006619701
SU048 ACSM1 16819 110087 0.132531165
SU048 NPM1 30 11079 0.002700513
SU048 OLFM2 13717 108695 0.112056008
SU048 PYHIN1 16 12952 0.001233806
SU048 SMC1A 181167 477095 0.275220201
SU048 TET2-D1384V 1797 15854 0.101807263
SU048 TET2-E1357STOP 7416 12117 0.379665182
SU048 ZMYM3 18518 288810 0.060254842
SU070 TET2-Y1649STOP 7732 8419 0.478731967
SU070 CXOFF36 3503 4537 0.435696517
SU070 CACNA1H 12083 12775 0.48608094
SU070 TET2-T1884A 4218 4552 0.480957811
SU070 CXOFF66 3678 4466 0.451620825
SU070 SCN4B 5086 11273 0.310899199
SU070 NCRNA00200 9199 16212 0.362008579
SU070 GABARAPL1 1648 3344 0.330128205
SU070 DOCK9 3382 5285 0.390215761
SU070 CTCF 10529 19561 0.349916916
SU070 PXDN 78 4712 0.016283925
SU070 TMEM20 157 14986 0.010367827
SU070 TMEM8B 69 7791 0.008778626
Table 3.3.3: Somatic Variations used in the re-analysis of the HSC targeted deep sequencing
dataset in Jan et al.
TET2-E1357STOP SMC1A ACSM1 OLFM2 TET2-D1384V
SMC1A 1
ACSM1 1 1
OLFM2 0.67 0.67 0.33
TET2-D1384V 0.75 0.5 0.25 0.25
ZMYM3 0.75 0.5 0.25 0.25 0.25
Table 3.3.4: Mutation co-localization frequency matrix for patient SU048 HSC targeted deep
sequencing data from Jan et al. Mutations are sorted in descending order by AF.
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frequency data but also across e.g. the primary and the relapse is lower, further trimming
the “solution space”, often to a single, unique structure. Using both simulations and
experimental data, we have extensively characterized and validated our methods. We
have illustrated with a number of datasets that this approach is often able to identify
key patterns underlying tumor progression and relapse, including information to guide
mutation prioritization.
In the case that the solution space cannot be further trimmed, we provide methods
to derive useful knowledge, in terms of mutation cluster co-localization and timing.
Our subclone structure enumeration procedure is exhaustive, and is free from the bi-
ases introduced by the choice of parameters or prior distributions often required for
statistical sampling of the subclone structure solution space. We demonstrated that the
co-localization and timing of mutations predicted from the HSC bulk targeted sequenc-
ing (Jan et al.) correlate well with their function, and can be used in a similar fashion
to prioritize functional study.
The analysis of previously published datasets and our own datasets suggests that
SubcloneSeeker will be applicable for a number of clinical / biological problems. Using
serous ovarian cancer as an illustrative example, we have demonstrated that chemore-
sistance and relapse in this disease is a clonally driven process, and that such clones
can be either present in the primary tumor or “arise” during progression or relapse.
The patterns of temporal mutational order and cellular co-localization provide clini-
cally relevant insight into the genomic basis for chemoresistance. In ovarian cancer,
80% of tumors are classified as chemosensitive while 20% of cancers progress during
or recur shortly after platinum-based adjuvant chemotherapy. Unfortunately, there are
no known genetic markers at present that can reliably predict inherent or acquired
chemoresistance. This is likely the result of the complex and multi-factorial biological
basis for this phenotype. However, whereas one or a small number of them may not
be informative, analysis of many resistant clones and identification of the correspond-
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ing mutational order and cellular co-localization may lead to a better understanding of
chemoresistance, and form a rational basis for targeting the chemoresistant clones.
We envision similar utility for this type of analysis in advancing the current under-
standing of genomic alterations involved in the pre-malignant phases of cancer. Once
again using ovarian cancer as a prototypical case, it has been established that TP53 mu-
tations are ubiquitous and early events in serous ovarian carcinogenesis [170]. How-
ever, the prevalence of other relapse somatic mutations is about 10% or less [170]
suggesting that the additional requirements for transformation may be met through a
combination of more diverse co-localized or temporally related somatic mutations (plus
possible contributions from epigenetics and other molecular alterations, etc.). Thus ge-
nomic investigation of putative precursor lesion for serous carcinoma using approaches
presented here is likely to identify subclonal hierarchies whose constituent mutations
define cooperative classes on oncogenic event whose sum total results in malignant
transformation.
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4
Summary & Future Prospect
D
ESPITE DECADES OF EFFORT, cancer still remain as one of the deadliest dis-
eases mankind struggles with. With the onset of high throughput genomic
profiling technologies, we were granted, for the first time, the power to
glimpse into the inner working of cancer genomics. However, it gradually became clear
that a cancer biopsy, much in contrast to normal tissues, exhibits high intra-tumoral ge-
nomic heterogeneity, as in the cells in an entire tumor sample are divided into groups of
genetically different subpopulations, or subclones. As it was indicated by several recent
studies (Section 1.4), the interrogation of the degree of the heterogeneity, the genomic
profiles of each subclone, and the evolution dynamics between samples (e.g. primary
105
and relapse) often holds the key to the further understanding of tumorigenesis, drug
resistance, or metastasis.
We realized this challenge early on (Section 2.1), and designed method to reconstruct
tumor subclone structure with a simplifying model that was biologically motivated (Sec-
tion 2.2). The method always returns a parsimonious solution that represents a linear
subclonal heritage. Although certain ambiguity exists, the method will result in accu-
rate structure for somatic events that are existing in more than 50% of the tumor cells.
Two dataset representing different cancer types, ovarian serious carcinoma (OV) and
Intracranal Germ Cell Tumors (IGCT), were analyzed with the method, and the results
are presented in Section 2.3 and Section 2.4. In the case of the OV dataset, based on
whether the relapse sample contained more subclones than the primary, the patients
were classified into two groups with trending significant difference in survival after the
second surgery. For the IGCT dataset, the analysis helped elucidating the complexity
of this rare disease [149]. This work was to our knowledge the first attempt to tackle
the subclonality issue with whole genome microarray and Next Generation Sequencing
(NGS) dataset, and our method was presented at The Cancer Genome Atlas (TCGA) 1st
Annual Scientific Symposium as an oral presentation (Nov, 2011).
One apparent weakness of the method mentioned above is that it only return one
structure, when in fact multiple structures may result in the same input data that is
the observed somatic events. We developed an extended version of the method to enu-
merate all possible structures followed by trimming (Section 3.2). Given n somatic
mutations (or mutation clusters), there are in total n! potential structures. Not all of
them are biologically plausible, as in order to achieve the same cell prevalence val-
ues found in the observation, some subclones in some structures need to be assigned
a negative subclone frequency (SF). These structures are discarded from any further
consideration. Simulation study showed that the size of the solution space is tightly
restricted by this property (Section 3.3.2).
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Realizing that related samples, such as the primary and relapse tumor samples from
the same patient, often represent different time points of the same evolution process,
we take advantage of these extra samples to further trim the solution space (Sec-
tion 3.2.3.3). The reanalysis of published dataset showed a successful example in which
the primary data alone resulted in 6 equivalent structures, yet only 1 of them was com-
patible to the unique relapse structure (Section 3.3.4). Utilizing a similar approach,
we showed that how subclone structure can be of potential help in identifying the “top”
candidates, among many somatic events, in the search for driver mutations which result
in chemoresistance (Section 3.3.5)
In cases when the solution space cannot be reduced to a single, unique solution, we
have developed a statistical framework to treat all the remaining structures as a distribu-
tion, and identify the probability any two mutations (or mutation clusters) co-localizing
in the same subclone. We showed an example in which our prediction of co-localization
correlated well with the biological functions of the mutated genes (Section 3.3.7), and
provided discussion in how it could be of value in understanding chemoresistance, and
in designing personalized treatments (Section 3.4).
That concludes all the constituents that are part of this dissertation work. The rest of
this chapter will be devoted to my thoughts regarding the future of cancer subclonality
research.
4.1 MORE ACCURATE SUBCLONE STRUCTURE RECONSTRUCTION
As it was pointed out in Chapter 3, often there exist multiple mathematically equiv-
alent and biologically plausible subclone structures for the same observation data. In
some situations, further trimming with extra samples (Section 3.2.3.3), or deriving mu-
tation co-localization knowledge (Section 3.2.4) is possible, but ultimately it would be
desirable to reduce this ambiguity to the minimal. Due to the fact that the linkage in-
formation is lost during large scale genomic profiling (Section 2.5), this is impossible
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with a pure mathematically approach. However, new experiments should be designed
with intra-tumoral heterogeneity in mind, and gather as much information as possible
regarding cellular linkage.
4.1.1 COLLECT ADDITIONAL DATA TYPES FROM THE SAME SAMPLE
In Chapter 3, the concept of Cell Prevalence (CP) was introduced as in what percent of
all cells does a specific somatic variation exist. Since the method heavily relies on the
clusters identified with the CP values, it is thus crucial to have accurate CP estimations,
something that is not easily achieved. Imagine that a SNV with 40% reads supporting
the alternate allele would corresponds to 80% CP, yet it is only true in copy number
neutral region in which two copies of the locus exist in all cells. The same observation
would correspond to 40% CP should the SNV fall within a heterozygous deletion region
where only one copy of the locus exists. With this instance, it is made clear that the copy
number information at the locus of the SNV in question, or allele specific copy number
state, will be of tremendous value in correcting the CP estimation. Consequently, data
gathered without copy number estimation in mind, such as exome sequencing, would
suffer from difficulties in CP correction. It is therefore important, for future cancer
genomic profiling experiments, to incorporate as many types of data as possible. The
same sample, being investigated simultaneously by whole genome sequencing, whole
exome sequencing, and Array comparative genome hybridization (aCGH), would yield
much better and conclusive results in subclone structure reconstruction, as it allows
better correction of CP values, as well as more data points be observed given the unified
framework (Section 3.2.1).
4.1.2 DESIGN EXPERIMENTS THAT SPECIFICALLY CONSIDER TUMOR SUBCLONALITY
Often the amount of cells used for DNA sample preparation is minuscule compared to
the entire tumor biopsy. It is therefore difficult to guarantee that the DNA sample pro-
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vides an accurate representation of the distribution of all (if not only partial) subclones.
There have been studies based on multiple spatially separated samples [118]. Other
studies took serial samples at multiple time points throughout the course of the disease
[106, 109, 115]. These spatially and / or temporally segregated samples, when pooled
together, or analyzed separately before merging, would provide much representative
view on the tumor subclone dynamics with much greater resolution.
Single cell colony assay is another fruitful path when it comes to mutation timing. In
Section 3.3.7, we utilized a dataset by Jan et al. [114], which contains targeted deep
sequencing on single cell colonies of HSCs, to demonstrate how our method was able to
correctly predict the co-localization of mutations. Genomic profiling on colonies derived
from single cells would allow direct observation on the linkage between mutations, and
would consequently provide valuable inputs to the solution trimming (Section 3.2.3.3)
step.
4.2 THE IMPACT OF NEW TECHNOLOGIES ON THE PROBLEM OF SUBCLONE
RECONSTRUCTION
Before the dawn of large scale genomic profiling techniques, such as aCGH and NGS, it
was impossible to interrogate cancer genomes into finer details, let alone the realization
and attempts to reconstruct the subclone structure. A wave of new technologies are
now on the horizon that promises further advancement. Two specific techniques, single
molecule sequencing and single cell sequencing, are of particular interest.
4.2.1 SINGLE MOLECULE SEQUENCING
One of the fundamental sources of ambiguity during subclone structure reconstruction
comes from the loss of linkage information as in whether two independently identified
variation events were from the same cell. A potential remedy, albeit with limited power,
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is to check if a single sequencing read spans the loci of both events. If the reads spanning
the loci either contain both events or none of them, the events were from the same cells.
Otherwise, if the events were mutually exclusive on the same read, chances are that
different subclones independently harbor one of these events. However, limited by the
length of the current generation of NGS, which is no longer than 250 bp [171], and the
somatic mutation rate of ~1 to ~100 per Mb in the whole exome [9], the number of
reads spanning two somatic events is too low to be of any practical use.
However, with the emergence of single molecule sequencing [172–177]methods that
promise much longer reads (> 1000 bp), the significance of the aforementioned signal
would be much more applicable. In addition, longer reads would also enable modified
versions of de novo genome assembly algorithms to assemble subclone genomes directly
from the sequencing data. New methods will need to be developed to handle mapping,
assembling, variant calling, and subclone structure reconstructing problems with the
unique properties of the new sequencing data types, but the result will be much more
accurate and less ambiguous.
4.2.2 SINGLE CELL SEQUENCING
Further up the culprit of uncertainty in structure reconstruction is the fact that the
cells, which are the ultimate unit of asexual inheritance, are broken down before ge-
nomic profiling. It is akin to the problem of phylogenetics, only the individual “species”
are mixed together, and from which a single observation is obtained. Should we be
able to obtain genomic profiles of individual cells, or “species”, we would then be able
to tap into the vast knowledge in the field of molecular phylogenetics [178, 179] and
phylogenomics [180, 181]. Single cell sequencing (SCS) [182–187], an emerging tech-
nology, provides just the mean. Several studies that utilizing SCS to investigate tumor
heterogeneity were mentioned in Section 1.4, and there have already been reports on
methods that reconstruct evolution history of tumors using SCS data [188–190].
111
Although success stories are many, SCS could pose a different type of inaccuracy.
In most of the studies, the number of cells investigated is between 20 to 100, which
cannot guarantee an unbiased sampling on the underlying tumor population that often
contain cells orders of magnitude more. Each individually determined genome, though,
would serve as good source of confirming or denying whether events co-localize in the
same cell, and help in the process of trimming equivalent structures resulting from the
analysis of bulk sequencing data.
4.3 CONCLUDING REMARKS
Cancer is a formidable foe the humanity faces together. 40 years after the declaration
of “War on Cancer” by then U.S. President Richard Nixon [191–194], it still remains
as a terminal disease. According to the 2010 United States Cancer Statistics [195],
the combined incidence rate among the top 10 cancer types is 458.2 per 100,000, or
roughly 1 in every 200 people, and the death rate is 1 in every 1,000. With the explosion
of high throughput genomic profiling technologies, we are starting to peek behind the
curtain and for the first time realizing the complexity of cancer genome. It is to my most
sincere wish that the work this dissertation presented, along with many others, would
be ultimately of help in shedding lights on the mystery of tumorigenesis, metastasis,
drug resistance, and other cancer related mechanisms, as well as facilitate the push in
advancing cancer treatments, such as personalized therapeutic strategy design, so that
mankind could ultimately be rid of the dire fate cancer brings.
112
A
Supplemental Materials
Materials that are relevant to this work, yet don’t really fit anywhere else, are organized
here.
A.1 COMPARISON OF PERFORMANCE AMONG TRAP, PHYLOSUB AND SUB-
CLONESEEKER, AND EXAMPLE OF SUBCLONESEEKER UTILIZING CNV
DATA BASED ON MICROARRAY
As mentioned in Chapter 3, while all three methods (TrAp, PhyloSub, and Subclone-
Seeker) attempt subclone reconstructions, TrAp and PhyloSub require as input raw al-
113
lele counts at individual Single Nucleotide Variation (SNV) sites, whereas Subclone-
Seeker expects Cell Prevalence (CP) estimates, ideally of clusters of variants with a
shared CP value. Using each method as prescribed by their authors, TrAp and Sub-
cloneSeeker are both able to refine the results originally published by Ding et al. [113];
PhyloSub and SubcloneSeeker were both used to analyze the hematopoietic stem cell
(HSC) bulk sequencing + single cell colony assay dataset from Jan et al. [114] and
produced comparable results.
We further tested and compared the performance of these packages on a dataset
consisting of ultra-deep sequencing based read count data at a set of 21 validated SNVs
from primary / relapse ovarian tumor samples with matched normal tissues. As TrAp
and PhyloSub are designed to work on the “raw” allele count measurements, we first
provided this input to each of these methods. The TrAp method ran out of memory,
and provided no output, which we assume is because the method is not able to handle
such high number of individual SNVs. PhyloSub did produce output that, we fear, was
minimally informative to a user wishing to understand the resulting subclone structures
(Figure A.1.1).
A.1.1 SUBCLONE RECONSTRUCTION BY TRAP AND PHYLOSUB, USING RAW 454 SEQUENC-
ING READ COUNTS FOR EACH SNVS
We first attempted to perform subclone reconstruction using the raw read counts of
21 validated somatic SNVs with 738x median and 1080x mean coverage, as this is the
format these packages are designed to take as their input. However, TrAp[152] (v0.3)
issued an OutOfMemory error with 4G memory allocated to the JVM, and PhyloSub
[153] (commit 540fdfb003, as of Jun 17, 2014) produced a partial order plot that
made little sense due to the high number of nodes and edges. The data used for the
analysis is shown in Table A.1.1
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A.1.2 SUBCLONE RECONSTRUCTION BY SUBCLONESEEKER, USING SNV CLUSTERS
We clustered the same 21 SNVs in Primary allele frequency (AF) — Relapse AF space,
and identified 4 clusters (Figure A.1.2). SubcloneSeeker produced two structures with
the primary clusters and one solution with the relapse clusters. One of the primary
structures was trimmed away during the primary / relapse tree merging, resulting in a
unique subclone structure for this patient.
A.1.3 SUBCLONESEEKER’S UNIQUE ABILITY TO PERFORM STRUCTURE RECONSTRUCTION
ON ADDITIONAL DATA TYPES
We obtained Copy Number Variation (CNV) segments from TCGA-13-0913 microarray
level 2 probe intensity data, and clustered them in Primary CP — Relapse CP space. The
reconstruction result (Figure A.1.3) suggests the same conclusion as the SNV data does
(Figure A.1.2, ancestral, as well as more recent, subclones in the primary are present in
the relapse.), although the exact structure for the primary tumor sample differs. This
is potentially due to that, although these two datasets were from the same patient, the
DNA samples are different preparations, resulting in different sampling on the under-
lying tumor cell population, and consequently would not necessarily correspond to the
same subclone structure / fraction distribution, or that each could be providing a partial
view on the overall subclone structure.
A.2 ADDITIONAL MATERIALS AND METHODS
A.2.1 SEQUENCING PROCEDURE FOR THE TCGA OVARIAN SERIOUS CARCINOMA DATASET
A.2.1.1 ILLUMINA LIBRARY CONSTRUCTION
DNA samples were constructed into Illumina Paired-end libraries according to a modi-
fied version of the manufacturer’s protocol (Paired-End Sample Preparation Guide, Part
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Figure A.1.2: Subclone structure reconstruction results based on SNV clusters of TCGA-13-
0913. Top) The clusters, as well as their centroid allele frequency values. Bottom) The pri-
mary, relapse, and merged primary / relapse pair structures identified by SubcloneSeeker.
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no. 1005063). Briefly, 500ng of native DNA was sheared into 200-500 bp fragments by
nebulization followed by end-repair, 3’-end adenylation and ligation of the Illumina PE
adapters using the Illumina Paired-End DNA Sample Prep Kit (Part no. PE-102-1001).
Fragments with sizes between 290 and 350 bps were selected using 2% agarose gel
electrophoresis. Ligation Mediated-PCR was performed for 18 cycles of amplification
using primers and enzyme mix supplied in the sample preparation kit. Purification
was performed with the QIAquick PCR purification kit (Qiagen, Part no. 28106) after
enzymatic reactions. Following the final PCR purification, quantification and size distri-
bution of the PCR products were determined using the Agilent Bioanalyzer 2100 DNA
7500 chip.
A.2.1.2 ILLUMINA DNA SEQUENCING
Library templates were prepared for sequencing using Illumina’s cBot cluster generation
system with TruSeq PE Cluster Generation Kits (Part no. PE-401-1001). Briefly, these
libraries were denatured with sodium hydroxide and diluted to 3-6 pM in hybridization
buffer in order to achieve a load density of ~800K clusters / mm2. Each library was
loaded in 3 lanes of a flow cell, and each lane was spiked with 2% phiX control library for
run quality control. The sample libraries then underwent bridge amplification to form
clonal clusters, followed by hybridization with sequencing primer. Sequencing runs
were performed in paired-end mode using the Illumina HiSeq 2000 platform. Using
the TruSeq SBS Kits (Part no. FC-401-1001), sequencing-by-synthesis reactions were
extended for 101 cycles from each end. Real Time Analysis software was used to process
the image analysis and base calling. Sequencing runs generated approximately 80-120
million successful reads (2x100bp) on each lane of a flow cell, yielding ~60Gb per
sample.
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A.2.1.3 ILLUMINA READ MAPPING
Illumina reads were aligned to Human NCBI Build 36 using BWA (bwa-0.5.9rc1). De-
fault parameters are used for alignment except for a 40 bp seed sequence, 2 mismatches
in the seed, and a total of 3 mismatches allowed. BAM files generated from alignment
of Illumina sequencing reads were preprocessed using GATK to recalibrate and locally
realign reads.
A.2.2 SUPPLEMENTAL METHODS REGARDING DATA ACQUISITION FOR THE IGCT SNP AR-
RAY DATASET
DNA copy number analysis were performed using the high resolution Illumina Human-
Omni2.5-8 (Omni2.5) BeadChip Kit (Illumina). In brief, 200ng genomic DNA was first
denatured by NaOH. After nebulization of the sample, isothermal whole genome am-
plification was conducted to uniformly increase the DNA amount. The amplified DNA
was enzymatically fragmented and hybridized to BeadChip for 16–24 h at 48 ◦C. After
washing off unhybridized and non-specifically hybridized DNA fragments, allele-specific
single-base extension reaction was performed to incorporate labeled nucleotides into
the bead-bound primers. Following multi-layer staining to amplified signals from the
labeled extended primers and final washing and coating, beadchips were imaged using
the Illumina iScan system. SNV calls were collected using the Illumina GenomeStudio
Version 2011.1 Genotyping Module 1.9.4. For improved CNV analysis, B allele frequen-
cys (BAFs) were calculated and probe intensity log2 R ratios (LRRs) were extracted after
re-clustering the raw data by applying the GenomeStudio clustering algorithms.
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Glossary
Agilent The company that produces Human
Genome CGH Microarrays. Details regard-
ing the Agilent 1M and 415K platform can be
found at http://www.genomics.agilent.
com/. 47, 49, 50
aneuploid Having a ploidy that is other than
2. 48, 71
angiogenesis The development of new blood
vessels. 2
BAM A binary file format widely used for stor-
ing sequencing reads alignments.. 20
chromothripsis a catastrophic phenomenon
that the chromosomes appear to be shattered
and then stitched back together. 3
diploid Having two copies of the complete
genome.. 45, 55, 56, 69, 71
emPCR emulsion-based PCR. 10, 12
ER-positive Endocrine receptor (estrogen or
progesterone receptor) positive. 3
kataegis a hypermutation region character-
ized by multiple base substitutions. 3
non-Hodgkin lymphoma Any of a large
group of cancers of lymphocytes (http://
www.cancer.gov/cancertopics/types/
non-hodgkin). 7
platinum therapy Chemotherapy with cis-
platin as the anti-neoplastic reagent. 53
ploidy The number of copies of a complete
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